

# CGRP sensory neurons promote tissue healing via neutrophils and macrophages


<https://doi.org/10.1038/s41586-024-07237-y>

Received: 4 August 2023

Accepted: 26 February 2024

Published online: 27 March 2024

Open access

 Check for updates

Yen-Zhen Lu<sup>1</sup>, Bhavana Nayer<sup>1,5</sup>, Shailendra Kumar Singh<sup>2,5</sup>, Yasmin K. Alshoubaki<sup>1,5</sup>, Elle Yuan<sup>1</sup>, Anthony J. Park<sup>1</sup>, Kenta Maruyama<sup>2,3</sup>, Shizuo Akira<sup>2</sup> & Mikael M. Martino<sup>1,2,4</sup>✉

The immune system has a critical role in orchestrating tissue healing. As a result, regenerative strategies that control immune components have proved effective<sup>1,2</sup>. This is particularly relevant when immune dysregulation that results from conditions such as diabetes or advanced age impairs tissue healing following injury<sup>2,3</sup>. Nociceptive sensory neurons have a crucial role as immunoregulators and exert both protective and harmful effects depending on the context<sup>4–12</sup>. However, how neuro-immune interactions affect tissue repair and regeneration following acute injury is unclear. Here we show that ablation of the Na<sub>v</sub>1.8 nociceptor impairs skin wound repair and muscle regeneration after acute tissue injury. Nociceptor endings grow into injured skin and muscle tissues and signal to immune cells through the neuropeptide calcitonin gene-related peptide (CGRP) during the healing process. CGRP acts via receptor activity-modifying protein 1 (RAMP1) on neutrophils, monocytes and macrophages to inhibit recruitment, accelerate death, enhance efferocytosis and polarize macrophages towards a pro-repair phenotype. The effects of CGRP on neutrophils and macrophages are mediated via thrombospondin-1 release and its subsequent autocrine and/or paracrine effects. In mice without nociceptors and diabetic mice with peripheral neuropathies, delivery of an engineered version of CGRP accelerated wound healing and promoted muscle regeneration. Harnessing neuro-immune interactions has potential to treat non-healing tissues in which dysregulated neuro-immune interactions impair tissue healing.

The design of successful regenerative medicine treatments requires leveraging the key factors that have pivotal roles in tissue healing. Modulating the immune system to promote tissue healing has demonstrated to be remarkably effective, since immune components coordinate a complex series of events that are critical for proper healing<sup>1,2</sup>. Unsurprisingly, the immune dysregulation that occurs as a consequence of ageing or conditions such as diabetes has a substantial negative effect on tissue healing and is often characterized by persistent inflammation at the injured site<sup>2,3</sup>. Another potentially important factor in tissue repair and regeneration is the nervous system. For instance, studies using neurotomy models have shown that peripheral nerves have an essential role in some animal species that are capable of regenerating tissues<sup>13–16</sup>. Other studies using nerve depletion in mouse, which are more specific to sensory neurons, have shown that nociceptive neurons and non-peptidergic C-fibres that express Gα<sub>i</sub>-interacting protein promote adipose tissue regeneration<sup>17</sup> and skin repair after UV-induced damage<sup>18</sup>, respectively. Nociceptive sensory neurons (also referred to as nociceptors) are specialized primary sensory neurons that have nerve endings in tissues such as skin, muscles and joints. They detect and respond to noxious stimuli including temperature, chemicals and inflammatory mediators<sup>19</sup>. Nociceptors have been shown to be critical immunoregulators with both protective and harmful effects<sup>4,20,21</sup>. For


example, nociceptors either diminish or exacerbate inflammation, enhance resistance to pathogens, or impede their clearance<sup>5–12</sup>. Therefore, given the immunomodulatory properties of nociceptors and the central role of the immune system in tissue repair and regeneration, we investigated the importance of peptidergic sensory neurons in tissue healing following acute injury, and examined whether neuro-immune interactions could be harnessed to promote tissue healing. Specifically, we used skin and muscle as relevant tissue models that are known to be innervated by nociceptors and in which repair and regeneration outcomes are considerably modulated by the immune system<sup>1–3,22,23</sup>.

## Tissue healing in the absence of sensory neurons

To determine the importance of sensory neurons during tissue healing after acute injury, we used the *Nav1.8<sup>cre</sup>/Rosa26<sup>DTA</sup>* mouse. In this mouse, Na<sub>v</sub>1.8<sup>+</sup> dorsal root ganglion (DRG) neurons, which mainly represent nociceptors involved in mechanical, cold and inflammatory pain, are ablated by the expression of diphtheria toxin fragment A<sup>5,7,8,10,12,24</sup> (DTA). *Rosa26<sup>DTA</sup>* littermates with intact Na<sub>v</sub>1.8-expressing sensory neurons were used as controls. As acute injury models, we selected full-thickness wounds in the dorsal skin<sup>25,26</sup> and volumetric muscle loss injuries in quadriceps<sup>23</sup>. The absence of Na<sub>v</sub>1.8-expressing

<sup>1</sup>European Molecular Biology Laboratory Australia, Australian Regenerative Medicine Institute, Monash University, Melbourne, Victoria, Australia. <sup>2</sup>Laboratory of Host Defense, World Premier International Research Center, Immunology Frontier Research Center, Osaka University, Osaka, Japan. <sup>3</sup>Department of Pharmacology, School of Medicine, Aichi Medical University, Aichi, Japan. <sup>4</sup>Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia. <sup>5</sup>These authors contributed equally: Bhavana Nayer, Shailendra Kumar Singh, Yasmin K. Alshoubaki.

✉e-mail: mikael.martino@monash.edu



**Fig. 1** **Na<sub>v</sub>1.8<sup>cre</sup> nociceptors that express CGRP mediate tissue healing via myeloid cells.** **a, b**, Full-thickness skin wounds were created in denervated (*Nav1.8<sup>cre</sup>/Rosa26<sup>DTA</sup>*) mice and littermate controls (*Rosa26<sup>DTA</sup>*). **a**, Wound closure evaluated by histomorphometric analysis on day 6 and day 10 post-injury (*Rosa26<sup>DTA</sup>* day 6, *n* = 14; *Nav1.8<sup>cre</sup>/Rosa26<sup>DTA</sup>* day 6, *n* = 12; day 10, *n* = 8). **b**, Representative histology at day 6 post-injury. Black arrows indicate wound edges and red arrows indicate tips of epithelium tongue. Scale bar, 1 mm. **c, d**, Volumetric muscle loss was evaluated on quadriceps of *Nav1.8<sup>cre</sup>/Rosa26<sup>DTA</sup>* and *Rosa26<sup>DTA</sup>* littermate controls. **c**, Extent of muscle regeneration was evaluated by histomorphometric analysis on day 8 and day 12 post-injury (day 8, *n* = 7; day 12, *n* = 10). **d**, Representative histology at day 12 post-injury (fibrotic tissue is stained blue; muscle tissue is stained red). Scale bar, 500 μm. **e**, Distribution of Na<sub>v</sub>1.8<sup>+</sup> sensory neurons (red) in skin and muscle of

*Nav1.8<sup>cre</sup>/Rosa26<sup>DTA</sup>* mice before and after injury. White lines indicate keratinocyte layers and nuclei are in blue. GT, granulation tissue area. Scale bars, 500 μm. The experiment was repeated independently four times. **f**, Expression of CGRP in skin and muscle before and after injury detected by immunohistochemistry. Scale bars: 500 μm (skin), 100 μm (muscle). The experiment was repeated independently four times. **g–j**, *Ramp1* deletion in myeloid cells using *LysM<sup>cre/+</sup>/Ramp1<sup>fl/fl</sup>* mice. *LysM<sup>cre/+</sup>* mice were used as controls. **g**, Wound closure was quantified on day 6 post-injury (*n* = 10). **h**, Representative skin histology. **i**, Muscle regeneration was quantified on day 12 post-injury (*n* = 10). **j**, Representative muscle histology. Boxes show median (centre line) and interquartile range (edges), whiskers show the range of values and dots represent individual data points. **a, c**, Two-way ANOVA with Bonferroni post hoc test for pairwise comparisons. **g, i**, Two-tailed Student's *t*-test. *P* values are indicated.

sensory neurons resulted in a significant delay in skin wound closure, which was evident through decreased epithelial migration, a reduced number of proliferative keratinocytes and wounds remaining largely open after six days (Fig. 1a, b and Extended Data Fig. 1a–g). Similarly, muscle regeneration was impaired in *Nav1.8<sup>cre</sup>/Rosa26<sup>DTA</sup>* mice, which were characterized by increased fibrotic tissue and reduced muscle tissue formation (Fig. 1c, d and Extended Data Fig. 1h).

Nociceptor terminals release neuropeptides in response to danger signals that include inflammatory cytokines commonly present in tissues after acute injury<sup>27,28</sup>. Thus, we investigated the distribution of Na<sub>v</sub>1.8<sup>+</sup> sensory neurons during skin and muscle healing following acute injury. To visualize Na<sub>v</sub>1.8<sup>+</sup> sensory neuron distribution and the neuropeptides that they express, we used *Nav1.8<sup>cre</sup>/Rosa26<sup>DTA</sup>* mice where tdTomato fluorescent protein expression is restricted to Na<sub>v</sub>1.8<sup>+</sup> sensory neurons. Tissue sections of *Nav1.8<sup>cre</sup>/Rosa26<sup>DTA</sup>* uninjured skin and muscle showed Na<sub>v</sub>1.8<sup>+</sup> sensory neuron distribution across the epidermis and dermis in skin and nearby connective tissues in muscle (Fig. 1e). Following skin and muscle injury, we observed that Na<sub>v</sub>1.8<sup>+</sup> sensory neuron endings growing in clusters into the granulation tissue, thus establishing innervation within the injured area during the healing process (Fig. 1e and Extended Data Fig. 2a). Na<sub>v</sub>1.8<sup>+</sup> neurons exhibited expression of calcitonin gene-related peptide (CGRP) and substance P, and no detectable expression of vasoactive intestinal peptide (VIP) or galanin (GAL) (Fig. 1f and Extended Data Fig. 2b–d). Similarly, in the DRG following both skin and muscle injuries, these neurons showed expression of CGRP and substance P in cell bodies

(Extended Data Fig. 2e, f). Additionally, the absence of CGRP signal in *Nav1.8<sup>cre</sup>/Rosa26<sup>DTA</sup>* mice pre- and post-tissue injury underscores the role of Na<sub>v</sub>1.8<sup>+</sup> nociceptors as primary sources of CGRP during skin and muscle healing and suggests that nociceptor-derived CGRP has a pivotal role in these processes (Extended Data Fig. 2g, h).

### CGRP effect on injury immune cells

To investigate whether CGRP mediates neuro-immune interactions that drive tissue healing, we generated mice in which immune cells or non-immune cells were unable to respond to CGRP. Bone marrow cells deficient for RAMP1<sup>29</sup>, a co-receptor that is essential for CGRP signalling, were transplanted into γ-irradiated wild-type or *Ramp1<sup>-/-</sup>* mice. Wild-type mice that received wild-type bone marrow cells or *Ramp1<sup>-/-</sup>* mice that received *Ramp1<sup>-/-</sup>* bone marrow cells were used as controls. Skin and muscle healing were severely impaired in wild-type mice reconstituted with *Ramp1<sup>-/-</sup>* cells compared with those with wild-type cells. Similarly, transfer of *Ramp1<sup>-/-</sup>* cells into *Ramp1<sup>-/-</sup>* mice impaired healing, whereas wild-type cells rescued skin repair and muscle regeneration (Extended Data Fig. 3a–d). Considering that myeloid cells such as neutrophils and monocytes/macrophages constitute the majority of immune cells in injured tissues undergoing repair or regeneration and can represent up to 50% of the total wound cells<sup>1,2,23,26</sup>, we hypothesized that CGRP promotes tissue healing by modulating myeloid cells. To investigate this, we produced mice that lacked CGRP signalling in myeloid cells by crossing *LysM<sup>cre</sup>* (*LyzM* is also known as *Lyz2*) mice with


*Ramp1* floxed (*Ramp1*<sup>fl/fl</sup>) mice<sup>30</sup>. The *LysM*<sup>cre/+</sup>/*Ramp1*<sup>fl/fl</sup> mice displayed a significant reduction in skin wound closure and muscle regeneration, compared with *LysM*<sup>cre/+</sup> control mice (Fig. 1g–j). The extent of healing impairment, characterized by a significant delay in skin wound closure and compromised muscle regeneration with high level of fibrotic area, was indeed very similar to that observed in *Nav1.8*<sup>cre</sup>/*Rosa26*<sup>tdT</sup> mice. Together, these results suggested that CGRP from *Nav1.8*<sup>+</sup> sensory neurons promotes tissue healing via myeloid cells. In addition, CGRP treatment in vitro had no significant effect on the proliferation of key cell types involved in skin and muscle healing, including fibroblasts, keratinocytes, myoblasts and endothelial cells (Extended Data Fig. 3e). Further supporting this observation, we found that keratinocytes and myoblasts have low expression levels of either *Ramp1* or calcitonin receptor-like receptor (*Calcrl*), which together form the CGRP receptor complex (Extended Data Fig. 3f). Finally, *Nav1.8*<sup>+</sup> nociceptors in granulation tissue were found to be surrounded by CD11b<sup>+</sup> myeloid cells, which consist mainly of neutrophils and monocytes/macrophages in the context of tissue healing after acute injury (Extended Data Fig. 3g).

To gain insights into the effect of *Nav1.8*<sup>+</sup> sensory neurons on immune cells during tissue healing, we analysed immune cell dynamics in injured tissues by flow cytometry. We focused on neutrophils, monocytes/macrophages, dendritic cells and T cells, because they constitute the predominant immune populations during tissue healing<sup>1,2,23,26</sup> (Extended Data Fig. 4a,b). Compared with control mice, *Nav1.8*<sup>cre</sup>/*Rosa26*<sup>DTA</sup> mice exhibited an increased number of neutrophils and pro-inflammatory Ly6C<sup>hi</sup> monocytes/macrophages in skin and muscle 3 days post-injury (Fig. 2a). Similarly, macrophages in *Nav1.8*<sup>cre</sup>/*Rosa26*<sup>DTA</sup> mice showed a delayed polarization towards an anti-inflammatory and pro-repair (M2-like) phenotype in both tissues, characterized by a lower expression of CD206, a well-established M2-like macrophage marker, at later stages of the healing process (Fig. 2a). Although the total number of monocytes/macrophages observed 3 days post-injury in the skin was higher in *Nav1.8*<sup>cre</sup>/*Rosa26*<sup>DTA</sup> mice compared with controls (Fig. 2a), this phenomenon was not evident in muscle, a difference that may be attributed to either the lower density of *Nav1.8*<sup>+</sup> nociceptors in injured muscle or variations in the dynamic accumulation of monocytes/macrophages between the two tissues. In both skin and muscle tissues, no major differences were observed in dendritic cells except for a lower number in the skin of *Nav1.8*<sup>cre</sup>/*Rosa26*<sup>DTA</sup> at a late time point (day 10 post-injury). However, some variations were noted in the counts of CD4 T cells,  $\gamma\delta$  T cells and cytotoxic (CD8) T cells 3 days post-injury (Extended Data Fig. 4c). Nevertheless, although these cell populations are recognized for their role in modulating tissue healing, their proportions were considerably lower in both *Rosa26*<sup>DTA</sup> and *Nav1.8*<sup>cre</sup>/*Rosa26*<sup>DTA</sup> tissues. They constituted 20–50 times fewer cells compared with neutrophils and monocytes/macrophages in skin and muscle, respectively (Extended Data Fig. 4d). Thus, although CGRP signalling on T cells may affect tissue healing to some extent, the profound impairment of tissue healing upon conditional *Ramp1* knockout in myeloid cells suggests nociceptor-derived CGRP promotes tissue healing after acute injury primarily by influencing myeloid cells (Fig. 1g–j). Overall, the data demonstrated that the absence of nociceptors resulted in an increase in neutrophils and inflammatory monocytes/macrophages. This in turn delayed the transition towards an anti-inflammatory and pro-repair phase<sup>1,2,26</sup>, leading to impaired tissue healing. Of note, these findings align with previous reports showing that nociceptor ablation leads to an increased local accumulation of neutrophils after skin<sup>5,8</sup> and lung<sup>9</sup> infection, as well as neutrophils and inflammatory macrophages in colitis<sup>10</sup> and brain infection<sup>12</sup>.

The increased number of neutrophils and inflammatory monocytes/macrophages observed in the absence of *Nav1.8*<sup>+</sup> sensory neurons, along with the delayed transition of macrophages towards an anti-inflammatory and pro-repair phenotype, suggested that CGRP may regulate these cells through multiple mechanisms. Thus, we investigated the effect of CGRP on neutrophils and macrophages in vitro. First,

we verified that these cells strongly express CGRP receptor subunits (Extended Data Fig. 5a,b). Then, we conducted migration assays and observed that CGRP severely inhibited neutrophil and macrophage migration towards common chemokines found in wounds (CXCL1 for neutrophils and CCL2 for macrophages) (Fig. 2b). Notably, cell migration was also inhibited to some extent in the absence of chemokines. However, CGRP did not inhibit cell migration in *Ramp1*<sup>-/-</sup> neutrophils and macrophages, confirming that CGRP signals via RAMP1–CALCRL to mediate its effects on these cells (Extended Data Fig. 5c). Next, we investigated the effect of CGRP on neutrophil and macrophage viability. CGRP triggered increased neutrophil and macrophage death in the presence of the inflammatory cytokines IL-1 $\beta$  and TNF, which are typically found in acute injuries. Notably, CGRP did not promote macrophage death when cells were cultured without inflammatory cytokines or with cytokines that induce an M2-like polarization, suggesting that CGRP elicits its effect on macrophage death during the inflammatory phase of tissue healing (Fig. 2c and Extended Data Fig. 5d). Subsequently, we explored whether CGRP influences neutrophil clearance by regulating macrophage efferocytosis. Stimulation with CGRP resulted in a marked increase of macrophage efferocytosis, both in the absence and presence of inflammatory cytokines (IL-1 $\beta$  and TNF) (Fig. 2d). Additionally, CGRP had no direct impact on macrophage Ly6C expression in vitro despite our earlier observation of an increased number of pro-inflammatory monocytes/macrophages (Ly6C<sup>hi</sup>) in injured tissues of mice lacking nociceptors (Extended Data Fig. 5e). This suggested that the high number of Ly6C<sup>hi</sup> monocytes/macrophages was probably a consequence of delayed neutrophil clearance and/or macrophage polarization. Finally, we tested whether CGRP accelerates macrophage polarization towards an M2-like phenotype. We found that in the presence of the typical anti-inflammatory cytokines IL-4 and IL-13 (IL-4/IL-13) or IL-10, CGRP treatment increased levels of the M2-like markers CD206 and arginase-1, respectively, indicating that CGRP accelerates polarization into an anti-inflammatory and pro-repair phenotype (Fig. 2e).

To validate inhibitory migration effects of CGRP in vivo, we used an adoptive transfer model in which tdTomato<sup>+</sup> bone marrow cells were systemically administered into *Rosa26*<sup>DTA</sup> control and *Nav1.8*<sup>cre</sup>/*Rosa26*<sup>DTA</sup> mice following skin and muscle injuries. One day after the transfer, relative accumulation of tdTomato<sup>+</sup> neutrophils and monocytes/macrophages in the injured tissues was assessed by flow cytometry. Compared with *Rosa26*<sup>DTA</sup> mice, *Nav1.8*<sup>cre</sup>/*Rosa26*<sup>DTA</sup> mice showed a significant increase in neutrophils and monocytes/macrophages into injured skin and muscle, suggesting that migration of these cell types into injured tissues was considerably increased (Fig. 2f). For validation of efferocytosis in vivo, we injected dead or dying tdTomato<sup>+</sup> neutrophils intradermally at the border of skin wounds. The relative number of monocytes/macrophages positive for tdTomato was then assessed by flow cytometry and was found to be significantly lower in *Nav1.8*<sup>cre</sup>/*Rosa26*<sup>DTA</sup> mice, demonstrating an impairment of efferocytosis (Fig. 2f). Finally, to assess neutrophil and macrophage cell death in vivo, we performed a TUNEL assay on injured tissue sections 3 days post-injury. Slightly fewer CD11b<sup>+</sup> cells were TUNEL-positive in *Nav1.8*<sup>cre</sup>/*Rosa26*<sup>DTA</sup> mice (Fig. 2g and Extended Data Fig. 5f). However, as observed in vitro, the effect on cell death was relatively modest. Thus, CGRP-induced cell death is probably not a major mechanism in vivo. Together, these data support a model in which nociceptor-derived CGRP promotes tissue healing by tightly regulating neutrophil and monocyte/macrophage dynamics, functions and phenotypes in injured tissues, resulting in a faster transition from a pro-inflammatory to a pro-healing phase. CGRP inhibits neutrophil and monocyte/macrophage migration into injured tissues and may further enhance neutrophil and inflammatory macrophage death in the presence of inflammatory cytokines. Meanwhile, CGRP increases neutrophil clearance by stimulating macrophage efferocytosis, which, together with a direct effect of CGRP on macrophage polarization, supports macrophages switching towards an anti-inflammatory and pro-repair phenotype. This model aligns



**Fig. 2 | CGRP regulates myeloid cell function during tissue healing.**

**a**, Analysis of neutrophil and monocyte/macrophage (Mo/MΦ) populations by flow cytometry during tissue healing. Geometric mean of fluorescence intensity (MFI) of CD206 in macrophages was used to assess M2-like polarization. Data are plotted in kinetic line plots showing mean  $\pm$  s.e.m. Skin: day 0, day 6 and day 10,  $n = 20$ ; day 3,  $n = 22$ ; and day 14,  $n = 12$ . Muscle: day 0,  $n = 16$ ; day 3,  $n = 20$ ; day 6, day 10,  $n = 18$ ; and day 14,  $n = 10$ . **b–e**, Neutrophils and macrophages were treated with saline (PBS, 0 nM CGRP) or CGRP (1 or 20 nM). Results are expressed as fold change over the PBS (0 nM CGRP) group. **b**, Transwell migration towards CXCL1 or CCL2 with or without CGRP ( $n = 6–8$ ). **c**, Cell death in response to CGRP and TNF plus IL-1 (neutrophils,  $n = 7$ ; macrophages,  $n = 6$ ). **d**, Macrophage efferocytosis of neutrophils after CGRP treatment with or without TNF/IL-1 ( $n = 4$ ). **e**, Macrophage polarization determined via CD206 and arginase-1

protein expression following CGRP and IL-4/IL-13 or IL-10 treatment ( $n = 6$ ). **f**, tdTomato<sup>+</sup> bone marrow cells were administered systemically on day 2 post-injury. Fold change of tdTomato<sup>+</sup> neutrophils and monocytes/macrophages in injured tissues on day 3 post-injury was assessed by flow cytometry. For efferocytosis, dead or dying tdTomato<sup>+</sup> neutrophils were injected in skin wound borders on day 3 post-injury. Fold change of tdTomato<sup>+</sup> endogenous monocytes/macrophages was assessed by flow cytometry 30 min post-injection ( $n = 6$ ). **g**, Death of CD11b<sup>+</sup> cells 3 days post-injury, assessed by TUNEL assay on injured tissue sections ( $n = 6$ ). Boxes show median (centre line) and interquartile range (edges), whiskers show the range of values. Dots represent independent experiments. **a–e**, Two-way ANOVA with Bonferroni post hoc test for pairwise comparisons. **f, g**, Two-tailed Student's *t*-test. *P* values are indicated. NS, not significant.


well with the function of neutrophils and macrophages during tissue healing. For instance, excessive mobilization of neutrophils and inflammatory monocytes/macrophages is generally associated with impaired wound healing<sup>1,2,26,31,32</sup>. Enhanced clearance rate of pro-inflammatory cells within injured tissues is also well-known to prevent excessive inflammation and facilitate the transition towards the pro-repair phase. Indeed, impaired tissue healing has been linked to delayed inflammatory cell death and a decrease in macrophage efferocytosis capability<sup>22,33,34</sup>.

### Mediation of the CGRP effect by TSP-1

To further understand the molecular mechanisms by which CGRP modulates neutrophils and macrophages, we analysed the transcriptome of bone marrow-derived neutrophils and macrophages after CGRP stimulation by RNA sequencing (RNA-seq). For both cell types, gene ontology (GO) analysis of differentially expressed genes (DEGs) between CGRP-treated and control groups identified biological processes that were congruent with the *in vitro* effects of CGRP. In addition, the biological processes reflected the differences in neutrophil and macrophage dynamics observed in tissue injuries of control and nociceptor-depleted mice. For instance, for both neutrophils and macrophages, pathways enriched in the upregulated DEGs included

cell death, whereas those among the downregulated DEGs included cell migration (for example, *Ccr2*, *Cx3cr1*, *Itgav* and *Itgb3*) (Fig. 3a and Extended Data Fig. 6a). Furthermore, pathways enriched in the upregulated DEGs were associated with tissue remodelling and differentiation in macrophages, featuring genes typically linked to an anti-inflammatory and pro-repair phenotype such as *Arg1*, *Cebpb*, *Stat3*, *Sgk1*, *Tgfb3*, *Tgm2* and *Vegfa*<sup>35</sup>. Finally, in response to CGRP, macrophages upregulated genes that are strongly associated with efferocytosis such as *Cd14*, *Clu*, *Slpr1*, *Rarg* and *Tgm2*<sup>36,37</sup> (Fig. 3a and Extended Data Fig. 6a). Crucially, we found that thrombospondin-1 (*Thbs1*)—which encodes TSP-1, a multifunctional extracellular matrix (ECM) protein that regulates many biological processes including tissue healing<sup>38</sup>—was the most upregulated gene in both neutrophils and macrophages (Fig. 3b). Further confirming that TSP-1 is expressed in response to CGRP via RAMP1–CALCRL, *Ramp1*<sup>-/-</sup> neutrophils and macrophages did not upregulate *Thbs1* after CGRP stimulation (Extended Data Fig. 6b). Moreover, TSP-1 levels after skin and muscle injuries were lower in *Nav1.8<sup>cre</sup>/Rosa26<sup>DTA</sup>* mice (Extended Data Fig. 6c).

Notably, it has been reported that macrophages are the primary source of TSP-1 in wounds, and the absence of TSP-1 leads to impaired wound healing and prolonged inflammation<sup>39,40</sup>. Furthermore, increasing evidence suggests that TSP-1 is an important regulator in immune responses<sup>41</sup>. Thus, similar to the assays performed with CGRP,



**Fig. 3 | CGRP upregulates TSP-1 in neutrophils and macrophages to mediate its activity.** **a, b**, RNA-seq analysis of CGRP-treated neutrophils and macrophages (1 nM or saline for 4 h). Differential gene expression was performed with limma-voom (false discovery rate (FDR) < 0.05). Fold change values returned by limma were used for pathway analysis with FDR < 0.05 to correct for multiple comparisons. **a**, GO enrichment analysis of significantly upregulated (red) and downregulated (blue) genes in CGRP-treated and saline-treated groups. **b**, Volcano plots showing DEGs with fold change > |1.5| between CGRP-treated and saline-treated groups. Significantly upregulated (red) and downregulated (blue) genes in CGRP-treated neutrophils and macrophages are shown ( $n = 3$ ). **c–f**, Neutrophils and macrophages were treated with saline (PBS, 0 nM TSP-1) or


TSP-1 (1, 10 or 100 nM). Results are expressed as fold change over the PBS (0 nM TSP-1) control group. Boxes show median (centre line) and interquartile range (edges), whiskers show the range of values. Dots represent independent experiments. **c**, Transwell migration towards a chemoattractant (CXCL1 or CCL2) after TSP-1 treatment ( $n = 3$  for neutrophils,  $n = 4$  for macrophages). **d**, Cell death in response to TSP-1 with or without TNF plus IL-1 ( $n = 4$ ). **e**, Macrophage efferocytosis of neutrophils after TSP-1 treatment ( $n = 4$ ). **f**, Macrophage M2-like polarization determined via CD206 and arginase-1 expression in response to TSP-1 and IL-4/IL-13 or IL-10 treatments (CD206,  $n = 8$ ; arginase-1,  $n = 4$ ). **c–f**, One-way ANOVA with Tukey post hoc test for pairwise comparisons. *P* values are indicated.

we tested whether TSP-1 affects neutrophil and macrophage migration and death, as well as efferocytosis and macrophage polarization. Although some reports have suggested that TSP-1 promotes neutrophil and macrophage migration<sup>41</sup>, we clearly observed an inhibition of migration when cells were treated with TSP-1, similarly to our observations with CGRP (Fig. 3c). Moreover, TSP-1 accelerated death of neutrophils and macrophages in a dose-dependent manner in the presence of inflammatory cytokines (Fig. 3d). Efferocytosis of neutrophils by macrophages was also greatly enhanced following macrophage treatment with TSP-1 (Fig. 3e), in line with a previous study suggesting that TSP-1 acts as a bridge between neutrophils and macrophages to facilitate efferocytosis<sup>41</sup>. Finally, TSP-1 enhanced expression of CD206 and arginase-1 in the presence of anti-inflammatory cytokines (IL-4/IL-13 or IL-10), demonstrating that TSP-1 accelerates macrophage polarization towards an anti-inflammatory and pro-repair phenotype (Fig. 3f). To further confirm that CGRP exerted its effects primarily via an autocrine or paracrine action of TSP-1, we tested the effect of CGRP upon short interfering RNA (siRNA)-mediated knockdown of *Thbs1* (Extended Data Fig. 6d). Only macrophages were used, as transfection of neutrophils is very challenging. Knockdown of *Thbs1* abolished the effects of CGRP on cell migration, death, efferocytosis and polarization, whereas scramble siRNA showed no effect on all these cellular processes (Extended Data Fig. 6e–h). To validate these effects in vivo, we administered TSP-1 in *Nav1.8<sup>Cre</sup>/Rosa26<sup>DTA</sup>* mice following skin and muscle injuries. TSP-1 delivery resulted in reduced numbers of neutrophils, monocytes/macrophages and inflammatory monocytes/macrophages (Ly6C<sup>hi</sup>) at day 3 post-injury. Additionally, TSP-1 led to an increase in CD206 expression at day 14 post-injury (Extended Data Fig. 6i). Together, these results provide clear support for the role of TSP-1 in mediating the immunomodulatory effect of CGRP on neutrophils and macrophages.

### eCGRP promotes diabetic tissue healing

There is evidence suggesting that CGRP has a role in wound healing. For example, mice lacking CGRP exhibit impaired skin wound healing<sup>42</sup>.

Additionally, CGRP application is likely to promote corneal repair<sup>43</sup>. Therefore, since we found that nociceptor-derived CGRP regulates neutrophils and macrophages to facilitate tissue healing, we investigated whether local delivery of CGRP could restore the impaired healing observed in mice ablated of nociceptors. CGRP is a small peptide, which poses a challenge in achieving sustained effects without immediate burst signalling when delivered locally into tissue, as it can rapidly signal to cells, diffuse away from the delivery site and undergo degradation. Moreover, for clinical application, a high concentration of CGRP circulating in the body is undesirable, owing to possible off-target effects<sup>44</sup>. Thus, we engineered CGRP to enhance retention and protection at delivery sites by fusing it to a sequence with a very high affinity for ECM components<sup>25,26,45</sup>. The ECM-binding sequence was fused to the N terminus of CGRP followed by a plasmin-sensitive sequence to allow the release of CGRP from ECM via proteolytic activity (Extended Data Fig. 7a,b). These modifications did not impair CGRP activity, as demonstrated by the preserved capacity of the engineered CGRP (eCGRP) to inhibit neutrophil and macrophage migration and induce cAMP in these cells via RAMP1–CALCRL (Extended Data Fig. 7c,d). As demonstrated previously<sup>25,26,45</sup>, the ECM binding enabled better retention of CGRP after delivery into tissues (Extended Data Fig. 7e,f). We then tested whether CGRP variants (wild-type CGRP and eCGRP) could promote closure of splinted skin wounds and the regeneration of quadriceps after volumetric muscle loss in *Nav1.8<sup>Cre</sup>/Rosa26<sup>DTA</sup>* mice. For skin, CGRP variants were delivered topically, whereas for muscle, they were delivered via a fibrin hydrogel. Both CGRP variants enhanced the extent, compared with saline control, of wound closure and muscle regeneration upon delivery of 1  $\mu$ g. Moreover, at a lower dose (250 ng) eCGRP promoted greater wound closure and muscle regeneration compared with wild-type CGRP (Extended Data Fig. 7g–j). Notably, delivering a relatively high dose of CGRP (10  $\mu$ g) into mice has been shown to contribute to peripheral nociceptive sensitization<sup>46</sup>. Thus we tested whether injection of CGRP variants induced pain (Extended Data Fig. 7k,l). Administration of wild-type CGRP or eCGRP into mouse hind paws did not elicit significant pain behaviours over the 48-h experiment. However, a transient and slight increase in thermal sensitivity was



**Fig. 4 | Delivery of eCGRP promotes tissue healing in diabetic mice.** **a**, CGRP expression in skin and muscle of *Nav1.8<sup>cre</sup>/Rosa26<sup>DTA</sup>* and diabetic (*Lepr<sup>db/db</sup>*) mice detected by immunostaining. CGRP, green; nuclei, blue. White lines indicate the keratinocyte layer. Scale bars, 300  $\mu$ m. The experiment was repeated independently 6 times. **b, c**, Saline, CGRP (500 ng) or equimolar eCGRP was delivered on *Lepr<sup>db/db</sup>* skin wounds at day 1 and day 3 post-injury. **b**, Wound closure was evaluated by histomorphometric analysis on day 10 post-injury (saline and eCGRP,  $n = 14$ ; CGRP,  $n = 12$ ). Boxes show median (centre line) and interquartile range (edges), whiskers show the range of values. **c**, Representative skin histology. Black arrows indicate wound edges and red arrows point to tips of epithelium tongue. Scale bar, 1 mm. **d, e**, Saline, CGRP (1  $\mu$ g) or equimolar eCGRP was delivered in *Lepr<sup>db/db</sup>* quadriceps volumetric muscle loss defect via a fibrin hydrogel. **d**, Muscle regeneration (represented

by the percentage of fibrotic tissue and muscle area) was evaluated by histomorphometric analysis on day 8 post-injury. Boxes show median (centre line) and interquartile range (edges), whiskers show the range of values ( $n = 10$ ). **e**, Representative histology (fibrotic tissue is stained blue; muscle tissue is stained red). Scale bar, 500  $\mu$ m. **f**, Numbers of neutrophils (CD11b<sup>+</sup> Ly6G<sup>+</sup> F4/80<sup>-</sup>) and monocytes/macrophages (CD11b<sup>+</sup> F4/80<sup>+</sup> Ly6G<sup>-</sup>), and expression of Ly6C and CD206 in macrophages (represented by MFI) in *Lepr<sup>db/db</sup>* skin wounds and muscle injuries treated with saline or eCGRP were quantified by flow cytometry. Skin:  $n = 6$ . Muscle: day 3,  $n = 8$  for saline,  $n = 7$  for eCGRP; day 7,  $n = 9$ . Data are plotted as kinetic line plots showing mean  $\pm$  s.e.m. **b, d**, One-way ANOVA with Tukey post hoc test for pairwise comparisons. **f**, Two-way ANOVA with Bonferroni post hoc test for pairwise comparisons.  $P$  values are indicated.

observed only for wild-type CGRP. This difference is probably owing to the binding of eCGRP to the ECM, which prevents an immediate burst of signalling after delivery<sup>25,26,45</sup>.

We next searched for a model with more clinical relevance compared with the *Nav1.8<sup>cre/+</sup>/Rosa26<sup>DTA</sup>* mice. Indeed, more than half of patients with diabetes develop peripheral neuropathy, characterized by the presence of dysfunctional peripheral nerves and a decrease in intraepidermal nerve fibres<sup>47,48</sup>. Consequently, the decrease in neuropeptide levels, including CGRP, may disrupt neuro-immune interactions crucial for tissue healing<sup>49,50</sup>. Indeed, patients with diabetes commonly experience chronic non-healing wounds, which represent the most prevalent and severe complication of the condition, alongside the development of muscle atrophy<sup>49–51</sup>. The diabetic *Lepr<sup>db/db</sup>* mouse is a model for type 2 diabetes that is commonly used to study impaired tissue healing, since it mimics some aspects of human chronic wounds, including immune dysregulation and peripheral neuropathies<sup>25,26,52</sup>. Additionally, it has been shown that *Lepr<sup>db/db</sup>* have impaired muscle regeneration<sup>53</sup>. Thus, we investigated the distribution of CGRP in *Lepr<sup>db/db</sup>* mice skin and muscle to confirm that these mice exhibited peripheral neuropathy. We observed a significant reduction in neuron-like structures expressing CGRP in both skin and muscle of *Lepr<sup>db/db</sup>* mice, mirroring the pattern seen in *Nav1.8<sup>cre/+</sup>/Rosa26<sup>DTA</sup>* mice (Fig. 4a and Extended Data Fig. 8a). This observation supported the use of diabetic mice to assess the regenerative potential of local CGRP delivery. Notably, wound closure and muscle regeneration was greatly

improved when injuries were treated with eCGRP, compared with saline control and wild-type CGRP (Fig. 4b–e). We also examined TSP-1 expression in granulation tissue post-eCGRP delivery, given the induction of TSP-1 expression by CGRP in neutrophils and macrophages. Immunostaining revealed a significant increase in TSP-1 deposition, colocalizing to some extent with myeloid (CD11b<sup>+</sup>) cells in skin and muscle granulation tissues (Extended Data Fig. 8b). Next, since neutrophil and macrophage dynamics were disrupted in *Nav1.8<sup>cre/+</sup>/Rosa26<sup>DTA</sup>* mouse injuries, we investigated whether eCGRP delivery modulated those cells in injured tissues (Extended Data Fig. 9). eCGRP delivery reduced the number of neutrophils and monocytes/macrophages in both skin and muscle injuries at early timepoints post-injury. Moreover, eCGRP delivery led to reduced levels of the pro-inflammatory marker Ly6C and increased the level of the anti-inflammatory marker CD206 in skin wounds (Fig. 4f). Indeed, high numbers of neutrophils and inflammatory macrophages in diabetic injured tissues are known to delay healing<sup>2,31,32</sup>. An abnormally high number of neutrophils in chronic wounds leads to an over-production of pro-inflammatory cytokines, reactive oxygen species and proteases<sup>54</sup>, and increased NETosis<sup>55</sup>. Similarly, failure to convert macrophages to an anti-inflammatory phenotype leads to high levels of pro-inflammatory cytokines and proteases<sup>32</sup>. Thus, we measured concentrations of inflammatory cytokines/chemokines and proteases in response to saline and eCGRP treatment. eCGRP resulted in a significant reduction of IL-1 $\beta$ , CCL2, CXCL2, MMP-2 and MMP-9 (Extended Data Fig. 9b)—factors that are known to impair tissue healing

when their levels are increased<sup>26,56,57</sup>. Thus, the results overall support the idea that the local delivery of eCGRP accelerates the transition of diabetic injured tissues towards an anti-inflammatory and pro-repair phase.

## Conclusion

CGRP and nociceptors have been shown to have immunomodulatory effects in various contexts<sup>7–12</sup>. For example, CGRP has a key role as an immunosuppressive mediator during sepsis<sup>58</sup>. Additionally, during bacterial infection, nociceptor-derived CGRP has been shown to induce an anti-inflammatory transcriptional programme in macrophages and suppress neutrophil recruitment<sup>12</sup>. However, the role of nociceptors during tissue healing after acute injury was unclear. This study reveals the existence of an important neuro-immune regenerative axis following acute tissue injury and highlights the intricate interplay between nociceptors, immune cells and tissue healing processes. We found that Na<sub>v</sub>1.8<sup>+</sup> sensory neurons expressing CGRP, which mostly represent nociceptors, extend into the granulation tissue formed after skin and muscle injuries and profoundly modulate neutrophil and macrophage dynamics during tissue healing. This neuro-immune modulation promotes the transition towards an anti-inflammatory and pro-repair phase, which ultimately facilitates the healing process. Mechanistically, we demonstrate that CGRP signalling in neutrophils and macrophages induces the expression of TSP-1, which in turn limits their accumulation and accelerates cell death in the presence of inflammatory cytokines. In addition, CGRP promotes neutrophil clearance via efferocytosis and boosts macrophage polarization into an anti-inflammatory and pro-repair phenotype via autocrine and paracrine effects of TSP-1 (Extended Data Fig. 10). Collectively, the mechanisms uncover important implications for advancing our understanding of the tissue healing process after acute injury. These findings also have significant implications for advancing regenerative medicine, particularly for patients with peripheral neuropathies, including those associated with conditions such as diabetes. Harnessing the potential of this neuro-immune regenerative axis opens new avenues for effective therapies, whether as standalone treatments or in combination with existing therapeutic approaches. Utilizing or mimicking neuro-immune interactions holds great promise for addressing chronic wounds and other non-healing tissues, in which dysregulated neuro-immune interactions have a pathologic role and impair tissue healing.

## Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41586-024-07237-y>.

- Julier, Z., Park, A. J., Briquez, P. S. & Martino, M. M. Promoting tissue regeneration by modulating the immune system. *Acta Biomater.* **53**, 13–28 (2017).
- Larouche, J., Sheoran, S., Maruyama, K. & Martino, M. M. Immune regulation of skin wound healing: mechanisms and novel therapeutic targets. *Adv. Wound Care* **7**, 209–231 (2018).
- Muire, P. J., Mangum, L. H. & Wenke, J. C. Time course of immune response and immunomodulation during normal and delayed healing of musculoskeletal wounds. *Front. Immunol.* **11**, 1056 (2020).
- Hanc, P., Messou, M. A., Wang, Y. & von Andrian, U. H. Control of myeloid cell functions by nociceptors. *Front. Immunol.* **14**, 1127571 (2023).
- Chiu, I. M. et al. Bacteria activate sensory neurons that modulate pain and inflammation. *Nature* **501**, 52–57 (2013).
- Riol-Blanco, L. et al. Nociceptive sensory neurons drive interleukin-23-mediated psoriasisiform skin inflammation. *Nature* **510**, 157–161 (2014).
- Maruyama, K. et al. Nociceptors boost the resolution of fungal osteoinflammation via the TRP channel-CGRP-Jdp2 axis. *Cell Rep.* **19**, 2730–2742 (2017).
- Pinho-Ribeiro, F. A. et al. Blocking neuronal signaling to immune cells treats streptococcal invasive infection. *Cell* **173**, 1083–1097.e1022 (2018).
- Baral, P. et al. Nociceptor sensory neurons suppress neutrophil and gammadelta T cell responses in bacterial lung infections and lethal pneumonia. *Nat. Med.* **24**, 417–426 (2018).
- Yang, D. et al. Nociceptor neurons direct goblet cells via a CGRP-RAMP1 axis to drive mucus production and gut barrier protection. *Cell* **185**, 4190–4205.e4125 (2022).
- Hanc, P. et al. Multimodal control of dendritic cell functions by nociceptors. *Science* **379**, eabm5658 (2023).
- Pinho-Ribeiro, F. A. et al. Bacteria hijack a meningeal neuroimmune axis to facilitate brain invasion. *Nature* **615**, 472–481 (2023).
- Kumar, A. & Brockes, J. P. Nerve dependence in tissue, organ, and appendage regeneration. *Trends Neurosci.* **35**, 691–699 (2012).
- Buckley, G., Wong, J., Metcalfe, A. D. & Ferguson, M. W. Denervation affects regenerative responses in MRL/MpJ and repair in C57BL/6 ear wounds. *J. Anat.* **220**, 3–12 (2012).
- Simoes, M. G. et al. Denervation impairs regeneration of amputated zebrafish fins. *BMC Dev. Biol.* **14**, 49 (2014).
- Rinkevich, Y. et al. Clonal analysis reveals nerve-dependent and independent roles on mammalian hind limb tissue maintenance and regeneration. *Proc. Natl Acad. Sci. USA* **111**, 9846–9851 (2014).
- Rabiller, L. et al. Pain sensing neurons promote tissue regeneration in adult mice. *NPJ Regen. Med.* **6**, 63 (2021).
- Hoefel, G. et al. Sensory neuron-derived TAF4A promotes macrophage tissue repair functions. *Nature* **594**, 94–99 (2021).
- Dubin, A. E. & Patapoutian, A. Nociceptors: the sensors of the pain pathway. *J. Clin. Invest.* **120**, 3760–3772 (2010).
- Talbot, S., Foster, S. L. & Woolf, C. J. Neuroimmunity: physiology and pathology. *Annu. Rev. Immunol.* **34**, 421–447 (2016).
- Baral, P., Udit, S. & Chiu, I. M. Pain and immunity: implications for host defence. *Nat. Rev. Immunol.* **19**, 433–447 (2019).
- Chazaud, B. Inflammation and skeletal muscle regeneration: leave it to the macrophages! *Trends Immunol.* **41**, 481–492 (2020).
- Ratnayake, D. et al. Macrophages provide a transient muscle stem cell niche via NAMPT secretion. *Nature* **591**, 281–287 (2021).
- Abrahamsen, B. et al. The cell and molecular basis of mechanical, cold, and inflammatory pain. *Science* **321**, 702–705 (2008).
- Martino, M. M. et al. Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing. *Science* **343**, 885–888 (2014).
- Tan, J. L. et al. Restoration of the healing microenvironment in diabetic wounds with matrix-binding IL-1 receptor antagonist. *Commun. Biol.* **4**, 422 (2021).
- Donnelly, C. R., Chen, O. & Ji, R. R. How do sensory neurons sense danger signals? *Trends Neurosci.* **43**, 822–838 (2020).
- Udit, S., Blake, K. & Chiu, I. M. Somatosensory and autonomic neuronal regulation of the immune response. *Nat. Rev. Neurosci.* **23**, 157–171 (2022).
- Tsujikawa, K. et al. Hypertension and dysregulated proinflammatory cytokine production in receptor activity-modifying protein 1-deficient mice. *Proc. Natl Acad. Sci. USA* **104**, 16702–16707 (2007).
- Clausen, B. E., Burkhardt, C., Reith, W., Renkawitz, R. & Forster, I. Conditional gene targeting in macrophages and granulocytes using *LysM<sup>Cre</sup>* mice. *Transgenic Res.* **8**, 265–277 (1999).
- Peiseler, M. & Kubes, P. More friend than foe: the emerging role of neutrophils in tissue repair. *J. Clin. Invest.* **129**, 2629–2639 (2019).
- Krzyszczak, P., Schloss, R., Palmer, A. & Berthiaume, F. The role of macrophages in acute and chronic wound healing and interventions to promote pro-wound healing phenotypes. *Front. Physiol.* **9**, 419 (2018).
- Maschalidi, S. et al. Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes. *Nature* **606**, 776–784 (2022).
- Rodrigues, M., Kosaric, N., Bonham, C. A., Gurtner, G. C. & Wound, Healing: a cellular perspective. *Physiol. Rev.* **99**, 665–706 (2019).
- Wynn, T. A. & Vannella, K. M. Macrophages in tissue repair, regeneration, and fibrosis. *Immunity* **44**, 450–462 (2016).
- Kourtzelis, I., Hajishengallis, G. & Chavakis, T. Phagocytosis of apoptotic cells in resolution of inflammation. *Front. Immunol.* **11**, 553 (2020).
- Cunin, P. et al. Clusterin facilitates apoptotic cell clearance and prevents apoptotic cell-induced autoimmune responses. *Cell Death Dis.* **7**, e2215 (2016).
- Lopez-Dee, Z., Pidcock, K. & Gutierrez, L. S. Thrombospondin-1: multiple paths to inflammation. *Mediators Inflamm.* **2011**, 296069 (2011).
- Soto-Pantoja, D. R. et al. Thrombospondin-1 and CD47 signaling regulate healing of thermal injury in mice. *Matrix Biol.* **37**, 25–34 (2014).
- Agah, A., Kyriakides, T. R., Lawler, J. & Bornstein, P. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. *Am. J. Pathol.* **161**, 831–839 (2002).
- Kaur, S. & Roberts, D. D. Emerging functions of thrombospondin-1 in immunity. *Semin. Cell Dev. Biol.* **155**, 22–31 (2023).
- Toda, M. et al. Roles of calcitonin gene-related peptide in facilitation of wound healing and angiogenesis. *Biomed. Pharmacother.* **62**, 352–359 (2008).
- Zidan, A. A. et al. Topical application of calcitonin gene-related peptide as a regenerative, antifibrotic, and immunomodulatory therapy for corneal injury. *Commun. Biol.* **7**, 264 (2024).
- Legrand, J. M. D. & Martino, M. M. Growth factor and cytokine delivery systems for wound healing. *Cold Spring Harb. Perspect. Biol.* **14**, a041234 (2022).
- Julier, Z. et al. Enhancing the regenerative effectiveness of growth factors by local inhibition of interleukin-1 receptor signaling. *Sci. Adv.* **6**, eaba7602 (2020).
- Shi, X. et al. Neuropeptides contribute to peripheral nociceptive sensitization by regulating interleukin-1 $\beta$  production in keratinocytes. *Anesth. Analg.* **113**, 175–183 (2011).
- Levy, D. M. et al. Immunohistochemical measurements of nerves and neuropeptides in diabetic skin: relationship to tests of neurological function. *Diabetologia* **35**, 889–897 (1992).

48. Pittenger, G. L. et al. Intraepidermal nerve fibers are indicators of small-fiber neuropathy in both diabetic and nondiabetic patients. *Diabetes Care* **27**, 1974–1979 (2004).
49. Pradhan, L., Nabzdyk, C., Andersen, N. D., LoGerfo, F. W. & Veves, A. Inflammation and neuropeptides: the connection in diabetic wound healing. *Expert Rev. Mol. Med.* **11**, e2 (2009).
50. Volmer-Thole, M. & Lobmann, R. Neuropathy and diabetic foot syndrome. *Int. J. Mol. Sci.* **17**, 917 (2016).
51. Parasoglou, P., Rao, S. & Slade, J. M. Declining skeletal muscle function in diabetic peripheral neuropathy. *Clin. Ther.* **39**, 1085–1103 (2017).
52. Sullivan, K. A. et al. Mouse models of diabetic neuropathy. *Neurobiol. Dis.* **28**, 276–285 (2007).
53. Nguyen, M. H., Cheng, M. & Koh, T. J. Impaired muscle regeneration in ob/ob and db/db mice. *ScientificWorldJournal* **11**, 1525–1535 (2011).
54. Wilgus, T. A., Roy, S. & McDaniel, J. C. Neutrophils and wound repair: positive actions and negative reactions. *Adv. Wound Care* **2**, 379–388 (2013).
55. Wong, S. L. et al. Diabetes primes neutrophils to undergo NETosis, which impairs wound healing. *Nat. Med.* **21**, 815–819 (2015).
56. Chen, J. et al. Targeting matrix metalloproteases in diabetic wound healing. *Front. Immunol.* **14**, 1089001 (2023).
57. Wetzler, C., Kampfer, H., Stallmeyer, B., Pfeilschifter, J. & Frank, S. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. *J. Invest. Dermatol.* **115**, 245–253 (2000).
58. Jusek, G., Reim, D., Tsujikawa, K. & Holzmann, B. Deficiency of the CGRP receptor component RAMP1 attenuates immunosuppression during the early phase of septic peritonitis. *Immunobiology* **217**, 761–767 (2012).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024



## Methods

### Ethical statement for animal experiments

Animal experiments were approved by the Monash Animal Research Platform ethics committee and the Animal Research Committee of the Research Institute for Microbial Diseases of Osaka University (approval numbers 13294, 13335, 17075, 14013 and 23006).

### Animals

Wild-type C57BL/6J mice were from the Monash Animal Research Platform. Sperm from *Nav1.8<sup>cre+/+</sup>* mice (B6.129-*Scn10a<sup>tm2(cre)Jnu</sup>*/H B6, stock ID EM:04582, European Mouse Mutant Archive) were used for in vitro fertilization to generate *Nav1.8<sup>cre+/-</sup>* mice on a C57BL/6J background. *Rosa26<sup>DTA+/+</sup>* mice (B6.129-*Gt(ROSA)26Sor<sup>tm1(DTA)Mrc</sup>*/J), strain 010527, Jackson Laboratory) were maintained on a C57BL/6J background. To delete sensory neurons expressing *Nav1.8*, *Nav1.8<sup>cre+/-</sup>* mice were bred with *Rosa26<sup>DTA+/+</sup>* mice to generate *Nav1.8<sup>cre+/-</sup>/Rosa26<sup>DTA+/-</sup>* mice. *Nav1.8<sup>cre-/-</sup>/Rosa26<sup>DTA+/-</sup>* littermates were used as controls. For visualizing *Nav1.8<sup>+</sup>* neurons, *Rosa26<sup>tdT</sup>* reporter mice (B6.Cg-*Gt(ROSA)26Sor<sup>tm14(CAG-tdTomato)Hze</sup>*/J, strain 007914, Jackson Laboratory) were bred with *Nav1.8<sup>cre+/-</sup>* mice to generate *Nav1.8<sup>cre+/-</sup>/Rosa26<sup>tdT+/-</sup>*. *Lepr<sup>db/db</sup>* mice (BKS.Cg-*Dock7<sup>mi</sup>+/+Lepr<sup>db</sup>*/J, strain 000642) were obtained from Jackson Laboratory. Mice were bred as heterozygotes to generate *Lepr<sup>db/db</sup>* and *Lepr<sup>db/+</sup>* littermates. B6.129S2-*Ramp1<sup>tm1.21suj</sup>* mouse sperm was kindly provided K. Tsujikawa and used for in vitro fertilization to generate *Ramp1<sup>fl/fl</sup>* mice. *Ramp1<sup>fl/fl</sup>* mice were generated by crossing *Ramp1<sup>fl/fl</sup>* mice with *CAG<sup>cre</sup>* mice (C57BL/6-Tg<sup>(CAG-cre)</sup>13Miy, RIKEN BioResource Research Center, strain 09807). Specific deletion of *Ramp1* in myeloid cells (*LysM<sup>cre+/-</sup>/Ramp1<sup>fl/fl</sup>* mouse) was done by crossing *Ramp1<sup>fl/fl</sup>* mice with *LysM<sup>cre+/-</sup>* mice (B6.129P2-*Lyzs<sup>tm1(cre)Jfo</sup>*, RIKEN BioResource Research Center, strain 02302). *LysM<sup>cre+/-</sup>* littermates were used as controls. To obtain mice constitutively expressing tdTomato, *Rosa26<sup>tdT</sup>* mice were crossed with B6.C-Tg(CMV-cre)1Cgn/J mice from Jackson Laboratory (strain 006054).

### Full-thickness skin wound model

Male 10- to 12-week-old mice were used for most experiments, except for experiment with CGRP variant delivery in which female (10- to 12-week-old non-diabetic or 12- to 14-week-old diabetic) mice were used. Full-thickness punch-biopsy wounds (5 mm in diameter) were created while mice were under isoflurane anaesthesia as described<sup>25,26</sup>. For analgesia, mice received subcutaneous administration of 0.1 mg kg<sup>-1</sup> buprenorphine. In non-diabetic mice, wounds were covered with a round seal spot plaster (22.5 mm, Livingstone International, Australia) secured with 3M surgical tape. In experiments involving CGRP delivery, a nylon ring (Zenith 5/16 inch and M8 Nylon Washer) was attached with superglue (UHU) to prevent wound contraction. Wounds received topical treatment with either 10 µl of saline (PBS) or a CGRP variant in PBS. Solutions were applied in two different dosages: 250 ng of CGRP or equimolar eCGRP on day 1 post-injury for the low dose, and 500 ng of CGRP or equimolar eCGRP on day 1 and day 4 post-injury for the high dose. For diabetic mice, 4 wounds were created and treated with PBS or CGRP variant in PBS (500 ng CGRP or equimolar eCGRP) on day 1 and day 3.

### Volumetric muscle loss model

Non-diabetic (10- to 12-week-old) and diabetic (12- to 14-week-old) male mice underwent isoflurane anaesthesia. For analgesia, mice received subcutaneous administration of 0.1 mg kg<sup>-1</sup> buprenorphine. A 1-cm unilateral incision was made, exposing the fascia. Muscle injuries were created either with a 3-mm biopsy punch or by excising a 3 mm × 5 mm segment of the quadriceps, including the rectus femoris muscle. In experiments involving CGRP delivery, muscle defects were covered with a fibrin matrix (40 µl total, 8 mg ml<sup>-1</sup> fibrinogen (Enzyme Research Laboratories), 12 U ml<sup>-1</sup> bovine thrombin (Sigma), 5 mM CaCl<sub>2</sub>, and

17 µg ml<sup>-1</sup> aprotinin (Roche, Sigma)) containing CGRP (250 ng or 1 µg for non-diabetic mice and 1 µg for diabetic mice) or equimolar eCGRP. The incision site was sutured with non-absorbable sutures.

### Adoptive transfer of bone marrow cells

Bone marrow cells (1 × 10<sup>7</sup>) from 6-week-old *Ramp1<sup>fl/fl</sup>* or wild-type C57BL/6J mice were intravenously injected into lethally irradiated 6-week-old recipient wild-type or *Ramp1<sup>fl/fl</sup>* mice that received 100 mg l<sup>-1</sup> neomycin sulfate for 2 weeks post-irradiation. Skin or muscle defect surgeries were performed 6 weeks after transplantation.

### Histological analysis

Skin wounds were collected using an 8-mm biopsy punch, fixed in 10% formalin at room temperature for 24 h, cut at the edge of the wounds, embedded in paraffin and sectioned at 4 µm until the centre of the wound was passed. Re-epithelialization was measured by histomorphometric analysis. Slides were stained with haematoxylin and eosin, and the centre of the wound was determined by measuring the distance between the panniculus carnosus muscle gap using Aperio ImageScope Viewer (Leica Biosystems). Closure was calculated as the ratio of epidermis closure to the length of the panniculus carnosus gap. Muscle injury sites, including the proximal and distal quadriceps segments, were collected, fixed in 10% formalin solution for 24 h, embedded in paraffin, and sectioned at 4 µm thickness for 5 depths, starting from the edge of the patella, passing the centre of the wound, up to the proximal end of the defect site. Cross-sections were stained with Masson's Trichrome. Muscle regeneration was determined by averaging the percentage of blue-stained fibrotic area (normalized to the total area) and the remaining non-fibrotic muscle area across five tissue section depths, using Aperio ImageScope.

### Immunohistochemistry for neuropeptides, TSP-1 and myeloid cells

Tissues and DRGs (L1–L6 vertebrae) were fixed in 4% paraformaldehyde, cryoprotected in 30% sucrose, and embedded in OCT compound for 10 µm cryosections. Sections were stored at -20 °C, thawed, permeabilized and blocked with 1% bovine serum albumin (BSA), 10% normal goat serum (NGS) or normal donkey serum in PBS for 1 h. Sudan Black B solution (0.1% in 70% ethanol) was applied for 10 min. For neuropeptide detection, primary antibodies were added in staining buffer (0.5% BSA, 5% NGS or 0.5% BSA, 5% normal donkey serum in PBS) overnight at 4 °C. The primary antibodies included rabbit anti-CGRP (66.7 µg ml<sup>-1</sup>, Sigma, C8198), rabbit anti-substance P (1:500, Thermo Fisher Scientific, 20064), rabbit anti-VIP (1:500, Thermo Fisher Scientific, 20077), and goat anti-galanin (1 µg ml<sup>-1</sup>, Abcam, 99452). For TSP-1 detection, sections were incubated with AffiniPure Fab Fragment goat anti-mouse IgG (H + L) at 100 µg ml<sup>-1</sup> (Jackson ImmunoResearch Labs, 115-007-003) in PBS for 2 h at room temperature, followed by mouse anti-thrombospondin-1 (5 µg ml<sup>-1</sup>, Thermo Fisher Scientific, 14-9756-82). For myeloid cell detection, slides were incubated with rat anti-mouse CD11b (5 µg ml<sup>-1</sup>, Thermo Fisher Scientific, 14-0112-82). Sections were washed and incubated with respective secondary antibodies for 1 h at room temperature. The secondary antibodies included F(ab')<sub>2</sub>-Goat anti-Rabbit IgG Alexa Fluor 488 (2.6 µg ml<sup>-1</sup>, Thermo Fisher Scientific, A-11070), donkey anti-goat IgG Alexa Fluor 488 (2.6 µg ml<sup>-1</sup>, Thermo Fisher Scientific, A-11055), goat anti-mouse IgG Alexa Fluor Plus 488 (2.6 µg ml<sup>-1</sup>, Thermo Fisher Scientific, A48286TR), and goat anti-rat IgG Alexa Fluor Plus 594 (2.6 µg ml<sup>-1</sup>, Thermo Fisher Scientific, A48264). Counterstaining with DAPI for 10 min and mounting with Fluoroshield followed. Imaging was done using Leica DMi8 fluorescent microscope and Leica SP8 inverted confocal microscope.

### Evaluation of neuropeptide expression

Skin and muscle samples from male *Nav1.8<sup>cre+/-</sup>/Rosa26<sup>tdT+/-</sup>* mice (10- to 12-week-old) were immunostained as detailed above, imaged

## Article

on a Leica DMI8 fluorescent microscope and processed using Fiji<sup>59</sup>. Binary images were created with an optimal threshold, and overlapping areas were determined by combining region of interest binary images. Area fraction values, indicating neuropeptide expression in  $\text{Na}_v1.8^+$  nerves, were calculated based on pixel ratios and converted using a built-in scale bar<sup>60,61</sup>.

### Immunofluorescence for Ki-67 and KRT14

Paraffin sections underwent 20-minute antigen retrieval in 10 mM sodium citrate buffer (pH 6.0), followed by PBS washes and 5-minute permeabilization (0.2% Triton X-100 in PBS). Blocking with 10% NGS in 1% BSA/PBS occurred for 2 h, and endogenous IgG was blocked with unconjugated affinity-purified F(ab) fragment anti-mouse IgG (H + L) ( $10 \mu\text{g ml}^{-1}$ , Jackson ImmunoResearch, AB\_2338476) for 1 h at room temperature. Staining overnight at 4 °C utilized rat anti-mouse Ki-67 ( $5 \mu\text{g ml}^{-1}$ , Thermo Fisher Scientific, 5698-82) and mouse anti-mouse cytokeratin 14 ( $4 \mu\text{g ml}^{-1}$ , Thermo Fisher Scientific, MA5-11599) in 1% NGS in PBS with 0.1% BSA. After PBS-T washes, incubation with secondary antibodies occurred: goat anti-mouse Alexa Fluor 647 ( $2 \mu\text{g ml}^{-1}$ , Thermo Fisher Scientific, A-21235) and goat anti-rat Alexa Fluor 488 ( $2.67 \mu\text{g ml}^{-1}$ , Thermo Fisher Scientific, A48262TR) for 1 h at room temperature, followed by PBS-T wash. Counterstaining with DAPI ( $1 \mu\text{g ml}^{-1}$ ) for 10 min at room temperature preceded mounting with Fluoroshield.

### TUNEL assay

The In Situ Cell Death Detection Kit, TMR red (Roche, 12156792910) was used, following the manufacturer's instructions on muscle and skin tissue cryosections. To detect  $\text{CD11b}^+$  cells, sections were incubated overnight at 4 °C with rat anti-mouse CD11b ( $5 \mu\text{g ml}^{-1}$ , M1/70, Thermo Fisher Scientific, 14-0112-82) in staining buffer. After PBS-T washes, sections were incubated with Alexa Fluor 488 goat anti-rat antibody ( $2.67 \mu\text{g ml}^{-1}$ , Thermo Fisher Scientific, A48262TR), washed with PBS-T, and counterstained with DAPI ( $1 \mu\text{g ml}^{-1}$ ) before mounting with Fluoroshield. Two tissue section levels were evaluated per sample to determine the percentage of TUNEL<sup>+</sup> apoptotic cells over total  $\text{CD11b}^+$  cells, examining three fields per section within the injury site.

### Fibroblast, keratinocytes, myoblasts and endothelial cell maintenance

Human umbilical vein endothelial cells (HUVECs; Sigma, 200P-05N) cultured in EGM-2 medium (Lonza, CC-4176) up to 3 passages, and primary mouse fibroblasts from C57BL/6 J mouse tails<sup>26</sup> (passages 2–3) were used. MCDB-131 medium (Thermo Fisher Scientific) with  $100 \text{ mg ml}^{-1}$  penicillin/streptomycin and 2 mM glutamine was employed for proliferation assays. C2C12 mouse myoblasts (CellBank Australia) were cultured in a 1:1 ratio of DMEM to F10 medium (2 mM glutamine, 10% FBS, 100 units  $\text{ml}^{-1}$  penicillin/streptomycin). HaCaT keratinocytes (a gift from R. Boyd) were cultured in DMEM without  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  (2 nM glutamine, 10% Chelex-treated FBS, 0.03 nM calcium chloride, 100 units  $\text{ml}^{-1}$  penicillin/streptomycin) for at least 3 passages. Cells obtained from vendors were authenticated and certified negative for *Mycoplasma* contamination. For proliferation assays, FBS was reduced to 2% or kept at 10% for 24 h. Detached with TrypLE, cells were seeded (2,000 cells per well for HUVECs, fibroblasts, HaCaTs; 1,000 cells per well for C2C12) and treated with CGRP (1 or 20 nM) or 10–20% FBS. Incubation for 48 h (fibroblasts, C2C12) or 72 h (HUVECs, HaCaTs) at 37 °C with 5%  $\text{CO}_2$  followed. Proliferation was determined using the CyQUANT Cell Proliferation Assay (Invitrogen), presented as fold change over basal proliferation (medium only). PerkinElmer EnVision multi-mode plate reader with EnSpire Manager software was used.

### Flow cytometry with tissue samples

Skin wounds were collected using an 8-mm biopsy punch, and muscle defects were dissected to isolate the quadriceps. Samples were

minced with scissors and subjected to two serial digestions with collagenase XI ( $1 \text{ mg ml}^{-1}$ ) at 37 °C (two times 20 min for skin, two times 15 min for muscle). After the first digestion, the supernatant was collected and mixed with neutralization buffer (DMEM/F12 with 10% FBS and 5 mM EDTA). The first collection was kept on ice and fresh collagenase XI was added to the undigested tissue for the second digestion. Digestion mixtures were passed through a 70- $\mu\text{m}$  cell strainer and stained with LIVE/DEAD Fixable Aqua dye (Thermo Fisher Scientific, 1:400 dilution in PBS) for 20 min on ice. Cells were incubated with TruStain FcX anti-CD16/32 ( $10 \mu\text{g ml}^{-1}$ ; clone 93, BioLegend) diluted in staining buffer (5% FBS and 2 mM EDTA in PBS) for 20 min and subsequently incubated with primary antibodies in staining buffer for a further 30 min on ice. The following anti-mouse antibodies from BioLegend were used: FITC anti-CD11b (clone M1/70,  $6.6 \mu\text{g ml}^{-1}$ ) or BV711 anti-CD11b (clone M1/70,  $2 \mu\text{g ml}^{-1}$ ); PE anti-F4/80 (clone BM8,  $4 \mu\text{g ml}^{-1}$ ); BV421 anti-Ly6G (clone 1A8,  $2 \mu\text{g ml}^{-1}$ ); BV711 anti-Ly6C (clone HK1.4,  $1 \mu\text{g ml}^{-1}$ ) or FITC anti-Ly6C (clone HK1.4,  $5 \mu\text{g ml}^{-1}$ ); PE-Cyanine7 anti-CD206 (clone C068C2,  $2.6 \mu\text{g ml}^{-1}$ ); APC anti-CD206 (clone C068C2,  $2 \mu\text{g ml}^{-1}$ ); PE-Cyanine7 anti-CD3 (clone 17A2,  $4 \mu\text{g ml}^{-1}$ ); BV711 anti-CD3 (clone 17A2,  $4 \mu\text{g ml}^{-1}$ ); APC anti-CD4 (clone GK1.5,  $2 \mu\text{g ml}^{-1}$ ); BV421 anti-CD8 (clone 53-6.7,  $2 \mu\text{g ml}^{-1}$ ); PE anti-TCR  $\beta$  (clone H57-597,  $2 \mu\text{g ml}^{-1}$ ); APC/Fire 750 anti-TCR  $\gamma/\delta$  (clone GL3,  $2 \mu\text{g ml}^{-1}$ ); PE-Cyanine anti-CD11c (clone N418,  $2 \mu\text{g ml}^{-1}$ ); APC/Fire 750 anti-MHC Class II (clone M5/114.15.2,  $2 \mu\text{g ml}^{-1}$ ). Cells were washed once with a large volume of staining buffer before analysis with BD LSR Fortessa X-20 and FlowJo software (BD Biosciences).

### Mouse bone marrow neutrophil and monocyte isolation

Bone marrow cells were flushed from femora and tibiae of C57BL/6 J mice (8- to 12-week-old) with HBSS without  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  containing 2% FBS and 1 mM EDTA. Cell suspension was passed through a 70- $\mu\text{m}$  strainer. Next, EasySep Mouse Neutrophil Enrichment Kit or EasySep Mouse Monocyte Isolation Kit (STEMCELL Technologies) was used to isolate neutrophils or monocytes according to the manufacturer's instructions. Neutrophils were resuspended in RPMI containing 100 units  $\text{ml}^{-1}$  penicillin/streptomycin and 10% FBS for cell migration assay and cell death assay or 2% FBS for efferocytosis. Monocytes were cultured in DMEM/F12 (Thermo Fisher Scientific) containing 10% FBS, 2–10 ng  $\text{ml}^{-1}$  M-CSF (PeproTech) and 100 units  $\text{ml}^{-1}$  penicillin/streptomycin for subsequent experiments. RAMP1 and CALCRL were detected on neutrophils and monocytes using rabbit anti-RAMP1 ( $8.5 \mu\text{g ml}^{-1}$ , Alomone Lab, ARR-021) and rabbit anti-calcitonin receptor-like receptor ( $5 \mu\text{g ml}^{-1}$ , Biorbyt, orb526584).

### Neutrophil cell death

Bone marrow-isolated neutrophils were cultured in RPMI 1640 medium (10% FBS). Cells were incubated with CGRP (1–20 nM, Tocris Bioscience, 83651-90-5) for 10 min, followed by treatment with IL-1 ( $5 \text{ ng ml}^{-1}$ ) and TNF ( $50 \text{ ng ml}^{-1}$ ) for 12 h at 37 °C with 5%  $\text{CO}_2$  to induce cell death. After 12 h, cells were washed with PBS and incubated with LIVE/DEAD Fixable Aqua dye (Thermo Fisher Scientific, 1:400 dilution) in PBS on ice for 20 min. Cell death was assessed using BD LSR Fortessa X-20 and FlowJo software (BD Biosciences).

### Macrophage cell death and polarization marker expression

Bone marrow cells from 8- to 12-week-old C57BL/6 J mice were flushed, filtered and cultured in conditioned medium (DMEM/F12 with 10% heat-inactivated FBS, 100 units  $\text{ml}^{-1}$  penicillin/streptomycin, and 20% L929 fibroblasts-conditioned medium) at 37 °C with 5%  $\text{CO}_2$ . After 7–9 days, differentiated macrophages were collected and seeded in 12-well or 6-well plates. The next day, cells were treated with CGRP (1 or 20 nM, Tocris Bioscience, 83651-90-5) for 20 min before exposure to mouse IL-1 ( $5 \text{ ng ml}^{-1}$ ) and TNF ( $50 \text{ ng ml}^{-1}$ ), IL-4 ( $2 \text{ ng ml}^{-1}$ ) and IL-13 ( $2 \text{ ng ml}^{-1}$ ), or IL-10 ( $2 \text{ ng ml}^{-1}$ ) (PeproTech Inc) for 24 or 72 h. Macrophages were detached with TrypLE (Gibco) containing 3 mM EDTA, stained with

LIVE/DEAD Aqua dye for 20 min on ice, and incubated with blocking solution (10  $\mu\text{g ml}^{-1}$  TruStain FcX anti-CD16/32 (clone 93, BioLegend)) for 20 min before staining with antibodies for 30 min on ice. Antibodies from BioLegend included PE anti-CD11b (clone M1/70, 1  $\mu\text{g ml}^{-1}$ ), BV711 anti-F4/80 (clone BM8, 2  $\mu\text{g ml}^{-1}$ ), APC anti-CD80 (clone 16-10A1, 0.5  $\mu\text{g ml}^{-1}$ ) and PE-Cyanine7 anti-CD206 (clone C068C2, 1  $\mu\text{g ml}^{-1}$ ). For intracellular staining, cells were fixed and permeabilized using FluoroFix Buffer and Intracellular Staining Permeabilization Wash Buffer (Perm buffer, BioLegend). APC anti-mouse arginase-1 (Thermo Fisher, Clone AlexF5, 1  $\mu\text{g ml}^{-1}$ ) was added to the Perm buffer and incubated with the cells for 30 min on ice. After washing with Perm buffer and staining buffer, cells were analysed using BD LSR Fortessa X-20 and FlowJo software (BD Biosciences).

### Neutrophil and macrophage migration

Assays were conducted using 6.5-mm-diameter culture plate inserts (Corning) with 5- $\mu\text{m}$  and 3- $\mu\text{m}$  pore sizes for macrophages and neutrophils, respectively. Macrophages ( $1 \times 10^5$ ) or neutrophils ( $3 \times 10^5$ ) in migration media (DMEM/F12 with 0.25% BSA) were added to the inserts. The lower chambers contained migration buffer alone or chemoattractant (mouse CCL2 10  $\text{ng ml}^{-1}$  for macrophages or mouse CXCL1/KC 150  $\text{ng ml}^{-1}$  for neutrophils, PeproTech) with or without CGRP. Cells were allowed to migrate through the insert membrane for 3-4 h at 37 °C with 5%  $\text{CO}_2$ . For macrophages, the inserts were then fixed with 4% paraformaldehyde, and cells on the upper side were removed. DAPI (1  $\mu\text{g ml}^{-1}$ ) was used to stain cells on the bottom side, and they were counted using a fluorescent microscope. For neutrophils, cells that migrated into the lower chamber were collected and counted using a haemocytometer. The data are presented as the fold change, calculated by dividing the number of cells that migrated in response to treatments by the number of cells that migrated spontaneously (migration media only).

### Efferocytosis

An efferocytosis assay kit (Cayman, 601770) was used following the manufacturer's instructions. Neutrophils were labelled with CFSE and cultured in RPMI with 2% serum for 12 h to induce cell death. Bone marrow-derived macrophages cultured for 7 days were seeded at a density of  $4 \times 10^5$  cells per well in a 6-well plate with DMEM/F12 containing 10% FBS and 100 units  $\text{ml}^{-1}$  penicillin/streptomycin. Prior to the assay, macrophages were pre-treated with CGRP (1 or 20 nM) for 24 h. Macrophages were collected, labelled with CytoTell Blue, and then incubated with CFSE-labelled dead/dying neutrophils at different ratios (1:1, 1:2, and 1:4) at 37 °C for 15 min. The reaction was stopped by washing cells with ice-cold PBS containing 5% FBS and 1 mM EDTA. Cells were analysed with BD LSR Fortessa X-20 and FlowJo software (BD Biosciences). Macrophages were identified by CytoTell Blue-positive staining, and the efferocytosis index was calculated as the percentage of CFSE-positive cells in CytoTell Blue-labelled macrophages.

### Adoptive transfer of tdTomato<sup>+</sup> cells for in vivo migration and efferocytosis

tdTomato<sup>+</sup> bone marrow cells from *CMV-cre/Rosa26<sup>tdTomato</sup>* male mice (8- to 12-week-old) were adoptively transferred into *Nav1.8<sup>cre</sup>/Rosa26<sup>DTA</sup>* and *Rosa26<sup>DTA</sup>* mice either directly after red blood cell lysis (migration assay) or following neutrophil isolation (efferocytosis assay). In the migration assay,  $1 \times 10^7$  cells were intravenously delivered on day 2 after skin or muscle injury. On day 3, collected tissues were analysed via flow cytometry to detect tdTomato<sup>+</sup> cells. For the efferocytosis assay, neutrophils were cultured in low serum (2%) for 24 h to induce cell death, and  $2 \times 10^6$  dead or dying neutrophils were intradermally injected at the skin wound border on day 3 post-injury. After 30 min, collected tissues were assessed via flow cytometry to quantify efferocytosis as the number of monocytes or macrophages that had taken

up tdTomato<sup>+</sup> apoptotic neutrophils. Results were presented as fold change relative to *Rosa26<sup>DTA</sup>* control mice.

### RT-PCR, qPCR and RNA-seq

Isolated neutrophils were treated with CGRP (1 nM) in RPMI with 10% FBS and 100 units  $\text{ml}^{-1}$  penicillin/streptomycin for 4 h at 37 °C with 5%  $\text{CO}_2$ . Isolated monocytes cultured in DMEM/F12 with 10% FBS, 100 units  $\text{ml}^{-1}$  penicillin/streptomycin, and M-CSF (10  $\text{ng ml}^{-1}$ ) for 3 days, had their medium replaced with CGRP (1 nM) for 4 h at 37 °C with 5%  $\text{CO}_2$ . After collection, RNA extraction used the RNeasy Plus Micro Kit (Qiagen). For PCR with reverse transcription (RT-PCR) and quantitative PCR (qPCR), reverse transcription used ReverTra Ace (Toyobo). RT-PCR primers were: Human\_Calcr1 5'-CATGCACATCC TTATGCAC-3' and 5'-CCATCACTGATTGTTGACAC-3'; Human\_Ramp1 5'-GCCAGGAGGCTAACTACG-3' and 5'-GAAGAACCTGTCCACCTCTG-3'; Mouse\_Calcr1 5'-GGTACCCTACTTGGCATTG-3' and 5'-GTCACCTGA TTGTTGACTG-3'; Mouse\_Ramp1 5'-GACGCTATGGTGTGACT-3' and 5'-GAGTGCAGTCATGAGCAG-3'. Human or mouse *GAPDH* primers were from Integrated DNA Technologies (51-01-07-12 and 51-01-07-13, respectively). PCR products were analysed by gel electrophoresis. qPCR was performed using LightCycle96 with software LightCycle96 (Roche Diagnostics) and TaqMan Assay primers from Thermo Fisher Scientific (*Thbs1*, Mm00449032\_g1; *Gapdh*, Mm99999915\_g1). For RNA-seq, RNA quantity and quality assessment, library preparation and sequencing were performed at the Medical Genomics Facility, Monash Health Translation Precinct (MHTP). RNA quantity was assessed using Qubit. RNA samples (20 ng) with RNA integrity number (RIN) value  $\geq 7$  were used for library preparation. First strand synthesis was performed using a dT primer which adds the Illumina P7 (5'-CAAGCAGAAGACGGCATAACGAGAT-3'), 8-bp i7 index for each sample and a 10-bp unique molecular identifier. The modified reverse transcriptase reaction also adds a template switching sequence at the 5' end of the RNA during the generation of indexed cDNA. These first strand indexed cDNA were pooled and amplified using primers to P7 and the template switch sequence. Illumina P5 was added by tagmentation by Nextera transposase during amplification. Standard Illumina R1 primer was used (main cDNA read), followed by standard i7 primer for index or unique molecular identifier. R2 primer was present but not used as it will read into poly-A tail. Sequencing was performed on the NextSeq2000 (Illumina), using NextSeq 1000/2000 P2 Reagents (100 cycles) v3 (Illumina) in accordance with the Illumina Protocol 1000000109376 v3 Nov2020.

### Demultiplexing and mapping

Fastq files were processed using the nfCore/RNAseq (v3.2) pipeline using the umi function<sup>62</sup>. Reads were aligned to the *Mus musculus* GRCm38 reference using STAR aligner<sup>63</sup>. Reads were quantified using featureCounts producing the raw genes count matrix and various quality control metrics which were summarized in a multiQC report<sup>64,65</sup>. Raw counts were analysed with Degust<sup>66</sup>, a web tool which performs normalization using trimmed mean of M values (TMM)<sup>67</sup>. Differential gene expression analysis was performed using limma/voom<sup>68</sup> in Degust and genes with a FDR-adjusted *P* value  $< 0.05$  were considered significantly upregulated or downregulated. Volcano plots were made using the web tool, VolcanoNoseR<sup>69</sup>. Gene ontology enrichment analysis for biological processes was performed with the web tool, ShinyGO 0.77, by providing all upregulated or downregulated DEGs separately as the input for each experimental group<sup>70</sup>.

### siRNA-mediated knockdown

Macrophages ( $4 \times 10^5$  cells per well in a 6-well plate) were transfected with 10 nM scrambled siRNA (Silencer Select Negative Control No. 1 siRNA, Thermo Fisher, 4390843) or Silencer Select Pre-Designed siRNA against mouse TSP-1 (Thermo Fisher, s124596) using Reduced-Serum Medium (Opti-MEM, Gibco) and Lipofectamine RNAiMAX (Invitrogen,

# Article

51985034) for 6 h. The medium was then replaced with fresh culture medium (DMEM/F12 with 10% FBS). After 24 h, cells were collected for the migration assay. For the efferocytosis assay, cells were cultured with 1 nM CGRP immediately after transfection. After 24 h, cells were collected and co-cultured with dead or dying neutrophils. The evaluation of cell death and polarization used the same methods as those for assessing macrophage death and polarization marker expression.

## CGRP variants

CGRP and eCGRP were synthesized by ProteoGenix. eCGRP was designed to contain PIGF residues 123–141 at the N terminus followed by a plasmin-sensitive sequence from vitronectin (KGYR)<sup>71</sup>. For both variants, a disulfide bond was formed between the two cysteine residues and the C-terminal phenylalanine was amidated. Peptide purity, determined by high performance liquid chromatography, was 89.63% for CGRP and 87.33% for eCGRP.

## Cleavage of eCGRP by plasmin

CGRP (4 µg) and equimolar eCGRP in 20 µl of PBS (pH 7.2) were incubated with plasmin (0.0005 U µg<sup>-1</sup>, Sigma) at 37 °C for 60 min. Aprotinin (25 µg ml<sup>-1</sup>, Sigma) was added for 5 min at 37 °C to stop plasmin activity. Samples were analysed by SDS–PAGE.

## Retention of CGRP and eCGRP into skin and muscle

CGRP (1 µg) or an equal molar amount of eCGRP was intradermally administered to the shaved dorsal skin of male 10- to 12-week-old *Nav1.8<sup>cre+/+</sup>/Rosa26<sup>tdTomato</sup>* mice, with injection sites marked using a marker. For muscle, CGRP variants were injected into the quadriceps. After 24 h, collected injection sites underwent cryosectioning and immunostaining. Fiji<sup>59</sup> was used for analysis, excluding the co-localization area of CGRP with tdTomato fluorescence, indicating endogenous CGRP expression.

## cAMP quantification

Freshly isolated neutrophils or bone marrow-derived macrophages (1 million cells) were treated with CGRP (1 nM) in RPMI with 10% FBS for 30 min at 37 °C with 5% CO<sub>2</sub>. cAMP levels were quantified using a cAMP ELISA kit from Cayman Chemical (581001) according to the manufacturer's instructions.

## Spontaneous pain behaviour assessment

Eight mice per group (4 males, 4 females, C57BL/6J, 10- to 12-week-old) were acclimatized for 1 h in empty cages. The right hind paw received an intraplantar injection of 1 µg of wild-type CGRP, equimolar amount of eCGRP, 0.05% capsaicin (Sigma, M2028), or 20 µl saline. Mice were immediately placed in the cage, and their behaviour was recorded. The number of episodes and the time spent licking, shaking, flinching and lifting the paw were recorded for first 5 min and for 5 min after 1, 6, 24 and 48 h.

## Hot plate test

Eight mice per group (4 males, 4 females, C57BL/6J, 10- to 12-week-old) received an intraplantar injection of 1 µg of wild-type CGRP, equimolar amount of eCGRP, or 20 µl saline in the right hind paw. After 30 min, mice were individually placed on a metal hot plate set to 52 °C. The latency, from mouse placement on the surface to the first behavioural sign of nociception (for example, lifting, shaking, licking the hind paw or jumping), was measured. Mice were immediately removed from the hot plate after responding or after a 30 s cut-off. The test was repeated after 1, 6, 24 and 48 h.

## ELISAs for cytokines and MMPs

Homogenized skin wound and muscle tissues were incubated for 30 min on ice in T-PER Tissue Protein Extraction Reagent (10 ml per g of tissue,

Thermo Fisher Scientific) containing 1 tablet of protease inhibitor for 7 ml (Roche). Samples were then centrifuged at 10,000g for 5 min and supernatants were stored at –80 °C. Total protein concentration was measured with a Bradford assay (Millipore). Cytokines and MMPs were detected by ELISA from R&D Systems; Mouse IL-1β/IL-1F2 DuoSet ELISA; Mouse CCL2/JE/MCP-1 DuoSet ELISA, Mouse CXCL2/MIP-2 DuoSet ELISA; Total MMP-2 Quantikine ELISA Kit; Mouse Total MMP-9 DuoSet ELISA.

## Statistical analysis

Statistical analyses were performed using GraphPad Prism 10 (GraphPad). Significant differences were calculated with Student's *t*-test, one-sample *t*-test, and by ANOVA when performing multiple comparisons between groups. *P* < 0.05 was considered as a statistically significant difference.

## Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

## Data availability

All data supporting the findings of this study are provided within the manuscript and its Supplementary Information. RNA-seq data generated for this study are deposited in the NCBI Gene Expression Omnibus under accession GSE255049. Source data are provided with this paper.

- Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. *Nat. Methods* **9**, 676–682 (2012).
- Adler, J. & Parmryd, I. Colocalization analysis in fluorescence microscopy. *Methods Mol. Biol.* **931**, 97–109 (2013).
- Price, T. J. & Flores, C. M. Critical evaluation of the colocalization between calcitonin gene-related peptide, substance P, transient receptor potential vanilloid subfamily type 1 immunoreactivities, and isolectin B4 binding in primary afferent neurons of the rat and mouse. *J. Pain* **8**, 263–272 (2007).
- Patel, H., Ewels, P. & Peltzer, A. nf-core/rnaseq: nf-core/rnaseq v3.2 - Copper Flamingo. *Zenodo* <https://doi.org/10.5281/zenodo.1400710> (2021).
- Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
- Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* **30**, 923–930 (2014).
- Ewels, P., Magnusson, M., Lundin, S. & Kaller, M. MultiQC: summarize analysis results for multiple tools and samples in a single report. *Bioinformatics* **32**, 3047–3048 (2016).
- Powell, D. R. drpowell/degust 4.1.1. *Zenodo* <https://doi.org/10.5281/zenodo.3258932> (2019).
- Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. *Genome Biol.* **11**, R25 (2010).
- Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol.* **15**, R29 (2014).
- Goedhart, J. & Luijsterburg, M. S. VolcanoR is a web app for creating, exploring, labeling and sharing volcano plots. *Sci. Rep.* **10**, 20560 (2020).
- Ge, S. X., Jung, D. & Yao, R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. *Bioinformatics* **36**, 2628–2629 (2020).
- Chain, D., Kreizman, T., Shapira, H. & Shaltiel, S. Plasmin cleavage of vitronectin. Identification of the site and consequent attenuation in binding plasminogen activator inhibitor-1. *FEBS Lett.* **285**, 251–256 (1991).

**Acknowledgements** The authors thank S. N. Lau and E. Tang for assistance with histology processing; A. Fernandes for assistance with the initial wound healing experiments; the Monash Histology Platform; T. Wilson for RNA-seq; the Monash Bioinformatics Platform for assistance with RNA-seq analysis; K. Tsujikawa for providing *Ramp1<sup>fl/+</sup>* sperm; M. Ikawa, K. Kaseda and N. Furuta for in vitro fertilization of *Ramp1<sup>fl/+</sup>* mice; H. Tanaka for assistance with *LysM<sup>Cre</sup>* mice transfer from RIKEN BioResource Research Center; and J. M. D. Legrand for detailed reading of the manuscript. Extended Data Fig. 10 was created with BioRender.com. This work was funded in part by the National Health and Medical Research Council (APP1140229 and APP1176213) to M.M.M., the Viertel Charitable Foundation Senior Medical Researcher Fellowship to M.M.M. and the Osaka University International Joint Research Promotion Program to S.A. The Australian Regenerative Medicine Institute is supported by grants from the State Government of Victoria and the Australian Government.

**Author contributions** M.M.M. conceptualized the initial study. Y.-Z.L. and M.M.M. designed the study and experiments. Y.-Z.L. performed most in vivo and in vitro experiments. B.N. performed in vivo flow cytometry, RNA-seq analysis, immunostaining and TUNEL assay. S.K.S. performed in vivo experiments. Y.K.A. performed in vivo flow cytometry and immunostaining. E.Y. performed proliferation assays and CGRP receptor expression. A.J.P. contributed to in vivo flow cytometry and mouse colony establishment. M.M.M. contributed to in vivo and in vitro experiments. K.M. initially established the *Nav1.8<sup>cre+/+</sup>*, *Rosa26<sup>Cre/+</sup>* and *Rosa26<sup>Cre/+</sup>* colonies and provided conceptual insights. S.A. provided conceptual insights, assisted with data

interpretation and supported the generation of transgenic mouse colonies. Y.-Z.L. and M.M.M. wrote the initial draft and created the figures. Y.-Z.L., B.N., S.K.S., Y.K.A., S.A. and M.M.M. edited the manuscript.

**Competing interests** Y.-Z.L. and M.M.M. are named as inventors on a patent application by Monash University relating to the molecular design described here. The other authors declare no competing interests.


**Additional information**

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41586-024-07237-y>.

**Correspondence and requests for materials** should be addressed to Mikaël M. Martino.


**Peer review information** *Nature* thanks Isaac Chiu and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

**Reprints and permissions information** is available at <http://www.nature.com/reprints>.



**Extended Data Fig. 1 | The lack of  $\text{Nav}_1.8^+$  sensory neurons impairs tissue healing.** **a–g**, Full-thickness skin wounds were created in *Nav1.8<sup>Cre</sup>/*Rosa26<sup>DTA</sup>** and littermate control *Rosa26<sup>DTA</sup>* mice. Wound closure was evaluated by histomorphometric analysis of tissue sections at D6 post-injury. Representative histology at the edge and centre of the wounds (**a**). Blue lines indicate wound edges. Purple lines indicate the epithelial tongue. GT indicates granulation tissue. Scale bar = 500  $\mu\text{m}$ . Wound closure was evaluated by macroscopic evaluation (**b**) to calculate the wound healing rate constant  $k$  (**c**) ( $n = 14$ ). Representative macroscopic images of the wounds (**d**). Scale bar = 5 mm. Measurement of the length of the migrating epithelial tongue (**e**) ( $n = 12$ ). Quantification of the number of proliferating keratinocytes (Ki-67 positive) in tissue sections (**f**) ( $n = 12$ ). Representative image of immunostaining for keratin

14 (K14, purple) detecting the epithelial tongue and Ki-67 positive cells (green) (**g**). Blue lines indicate wound edges. Scale bar = 500  $\mu\text{m}$ . In **b**, data are plotted in kinetic line plots showing mean  $\pm$  SEM. In **c**, **e**, **f**, data are plotted in box plots showing median (centre line) and IQR (bounds). Whiskers show min. to max. range. Dots represent individual wounds. Two-way ANOVA with Bonferroni *post hoc* test for pair-wise comparisons in **b**. Two-tailed Student's *t*-test in **c**, **e**, **f**. *P* values are indicated; n.s., non-significant. **h**, Volumetric muscle loss was performed on the quadriceps of *Nav1.8<sup>Cre</sup>/*Rosa26<sup>DTA</sup>** and *Rosa26<sup>DTA</sup>* littermate control mice. Representative histology is shown (fibrotic tissue is stained blue; muscle tissue is stained red). Scale bars = 500  $\mu\text{m}$ . Repeated independently 7 times for D8 and 10 times for D12.




**Extended Data Fig. 2** | See next page for caption.

## Article

**Extended Data Fig. 2 | Na<sub>v</sub>1.8<sup>+</sup> sensory neurons mainly express CGRP during skin and muscle healing.** **a**, Quantification of Na<sub>v</sub>1.8<sup>+</sup> sensory neurons in skin and muscle before and after injury. Results are expressed as the percentage of tissue area positive for tdTomato in healthy tissue at D0 (uninjured) and in the granulation tissue at D3 and D6 post-injury ( $n = 4$ ). **b–d**, Expression of neuropeptides in skin and muscle were detected by immunohistochemistry (neuropeptides, green; Na<sub>v</sub>1.8, red; nuclei, blue). Scale bars = 500  $\mu\text{m}$  in skin and 100  $\mu\text{m}$  in muscle. Quantification of neuropeptide signal in Na<sub>v</sub>1.8<sup>+</sup> sensory neurons (**d**) ( $n = 4$ ). **e**, Neuropeptide expression in DRGs before and on D3 and D6 after skin and muscle injury (neuropeptides, green; Na<sub>v</sub>1.8, red; nuclei, blue). Scale bar = 100  $\mu\text{m}$ . Percentage of Na<sub>v</sub>1.8<sup>+</sup> cell bodies expressing a neuropeptide


type (**f**) ( $n = 3$ ). **g**, CGRP localisation in skin and muscle before and after tissue injury in *Nav1.8<sup>Cre</sup>/Rosa26<sup>DTA</sup>* and *Rosa26<sup>DTA</sup>* littermate control mice. White lines indicate the separation between the granulation tissue (GT) and the top of the wound in skin and the separation between the granulation tissue and the muscle tissue in muscle. Scale bars = 100  $\mu\text{m}$ . Quantification of CGRP signal (**h**) ( $n = 4$ ). In **a, d, h**, data are plotted in box plots showing median (centre line) and IQR (bounds). Whiskers show min. to max. range. Dots represent independent injuries. In **f**, data are plotted as bar graph showing mean  $\pm$  SD. Dots represent individual DRGs. One-way ANOVA with Tukey *post hoc* test for pair-wise comparisons in **a, d**. Two-way ANOVA with Bonferroni *post hoc* test for pair-wise comparisons in **f, h**. *P* values are indicated.






**Extended Data Fig. 3 | CGRP signalling in immune cells mediates skin and muscle healing.** **a-d**, Wildtype (wt) or *Ramp1*<sup>-/-</sup> mice were γ-irradiated and received a bone marrow transplant from wt or *Ramp1*<sup>-/-</sup> donor mice. Full-thickness skin wounds or quadriceps volumetric muscle loss were performed. Wound closure was evaluated by histomorphometric analysis of tissue sections at D6 post-injury (**a**) (*n* = 8). Representative histology (**b**). Black arrows indicate wound edges. Red arrows indicate tips of epithelium tongue. Scale bar = 1 mm. The extent of muscle regeneration (represented by the percentage of fibrotic tissue and muscle area) was evaluated by histomorphometric analysis of tissue sections at D12 post-injury (**c**) (*n* = 7). Representative histology D12 post-injury (fibrotic tissue is stained blue; muscle tissue is stained red) (**d**). Scale bar = 500 μm. **e**, Cell proliferation in response to CGRP treatment (2% FBS; *n* = 5 for keratinocytes, *n* = 4 for all other cell types; 10% FBS; *n* = 6 for fibroblasts and endothelial cells, *n* = 4 for keratinocytes and myoblasts). Foetal bovine serum

(FBS, 10%–20%) was used as a positive control and results are expressed as fold change over saline control (0 nM CGRP with 2% or 10% FBS). For gel source data, see Supplementary Fig. 1. **f**, *Calcr1* and *Ramp1* expression in fibroblasts, keratinocytes, myoblasts, and endothelial cells, detected by RT-PCR. *Gapdh* was used as the housekeeping gene. Repeated independently 3 times. **g**, Representative images showing the close proximity of CD11b<sup>+</sup> cells with Na<sub>v</sub>1.8<sup>+</sup> sensory neurons in granulation tissue 6D after skin and muscle injury (CD11b, green; Na<sub>v</sub>1.8, red; nuclei, blue). Scale bar = 50 μm. Repeated independently 4 times. All data are plotted in box plots showing median (centre line) and IQR (bounds). Whiskers show min. to max. range. Dots represent individual injuries or experiments. Two-tailed Student's *t*-test in **a,c**. Two-tailed one-sample *t*-test over fold increase of 1 in **e**. *P* values are indicated; n.s., non-significant.




**Extended Data Fig. 4 | Analyse wound immune cell dynamics in injured skin and muscle.** **a**, Gating strategy to analyse myeloid cells in skin and muscle post-injury. Flow cytometry dot plots representing the step by step (1–6) gating strategy to identify neutrophil (CD11b<sup>+</sup>, Ly6G<sup>+</sup>, F4/80<sup>-</sup>) monocytes/macrophages (Mo/M $\phi$ ; CD11b<sup>+</sup>, F4/80<sup>+</sup>, Ly6G<sup>-</sup>), and dendritic cells (CD11c<sup>+</sup>, MHC-II<sup>+</sup>). MFI is the geometric-mean of fluorescence intensity. **b**, Gating strategy to analyse T cells in skin and muscle post-injury. Flow cytometry dot plots representing the step by step (1–6) gating strategy to identify CD4 T cells (CD3<sup>+</sup>, CD4<sup>+</sup>), cytotoxic

T cells (CD3<sup>+</sup>, CD8<sup>+</sup>), and  $\gamma\delta$  T cells (CD3<sup>+</sup>, TCR $\beta$ <sup>-</sup>, TCR $\gamma\delta$ <sup>+</sup>). **c**, Numbers of dendritic and T cells in skin and muscle injuries analysis measured by flow cytometry. Data are plotted in kinetic line plots showing mean  $\pm$  SEM (Skin:  $n = 8$  for D0,  $n = 10$  for the other time points. Muscle:  $n = 8$ ). Two-way ANOVA with Bonferroni *post hoc* test for pair-wise comparisons. *P* values are indicated; n.s., non-significant. **d**, Bar graph representation of the average number of neutrophils, Mo/M $\phi$ , dendritic cells, and T cells in injured tissue at D3 post-injury in *Rosa26<sup>DTA</sup>* and *Nav1.8<sup>Cre</sup>/Rosa26<sup>DTA</sup>* mice.



**Extended Data Fig. 5 | CGRP expression in neutrophils and macrophages, its effects on *Ramp1*<sup>-/-</sup> cells, M2-Like macrophages, Ly6C expression, and CD11b<sup>+</sup> cell apoptosis.** **a**, *Calcrl* and *Ramp1* expression in bone marrow-derived neutrophils and macrophages detected by RT-PCR. *Gapdh* was used as the housekeeping gene. Repeated independently 3 times. For gel source data, see Supplementary Fig. 1. **b**, CALCRL and RAMP1 expression was detected in bone marrow-derived neutrophils and macrophages using immunostaining. CALCRL, green; RAMP1, red; nuclei, blue. Scale bars = 25  $\mu$ m. Repeated independently 3 times. **c**, Neutrophils and macrophages derived from mouse bone marrow of *LysM<sup>Cre/+</sup>/Ramp1<sup>fl/fl</sup>* were treated with saline (PBS, 0 nM CGRP) or CGRP (1 nM) and transwell migration towards a chemoattractant (CXCL1 or CCL2) was tested ( $n = 4$ ). Results are expressed as fold change over the saline PBS/0 nM CGRP control group. **d,e**, Bone marrow-derived macrophages were

treated with saline (0 nM CGRP) or CGRP (1 or 20 nM). Cell death in response to CGRP when macrophages were cultured with anti-inflammatory cytokines (IL-4/IL-13, or IL-10) (**d**) ( $n = 6$ ). Ly6C expression in response to CGRP treatment after macrophage culture in inflammatory (TNF/IL-1) or anti-inflammatory conditions (IL-10) (**e**) ( $n = 6$ ). Results are expressed as fold increase over treatment without CGRP and without cytokines. MFI is the geometric-mean of fluorescence intensity. **f**, Representative images of TUNEL assay at D3 post-injury in *Rosa26<sup>DTA</sup>* and *Nav1.8<sup>Cre</sup>/Rosa26<sup>DTA</sup>* mice (CD11b, green; TUNEL, red; nuclei, blue). Scale bar = 100  $\mu$ m. Repeated independently 6 times. All data are plotted in box plots showing median (central line) and IQR (bounds). Whiskers show min. to max. range. Dots represent independent experiments. Two-way ANOVA with Bonferroni *post hoc* test for pair-wise comparisons. n.s., non-significant.



Extended Data Fig. 6 | See next page for caption.


**Extended Data Fig. 6 | TSP-1 mediates the activity of CGRP on neutrophils and macrophages.** **a**, Differentially expressed genes contributing to GO enrichment analysis of CGRP-treated neutrophils and macrophages. Neutrophils and monocytes/macrophages were treated with CGRP (1 nM) or saline for 4 h. Transcriptomic profiling was performed by bulk RNA sequencing. Heatmap of selected significantly upregulated and downregulated genes depicting standardised gene expression values (z-scores) in CGRP-treated cells compared to PBS-treated cells. Individual biological replicates are shown ( $n = 3$ ). Genes are displayed in alphabetical order and further classified according to known functions indicated by the coloured circles next to the heat map. **b**, *Thbs1* expression after CGRP (1 nM) stimulation for 4 h in neutrophils and macrophages isolated from *LysM<sup>Cre+/+</sup>* and *LysM<sup>Cre+/+</sup>/Ramp1<sup>fl/fl</sup>* mice ( $n = 3$ ). Dots represent independent experiments. Horizontal bars show mean. Whiskers show min. to max. range. **c**, TSP-1 concentration in skin and muscle before (uninjured) and at D3 post-injury quantified by ELISA ( $n = 4$ ). **d**, Knockdown (KD) efficiency of TSP-1 by siRNA verified by qPCR analysis in macrophages. Results are expressed as relative expression over cells transfected with scramble siRNA ( $n = 6$ ). **e–h**, Macrophages derived from mouse bone marrow were transfected with

scramble siRNA or *Thbs1* siRNA and treated with saline (PBS, 0 nM CGRP) or CGRP (1 nM). Results are expressed as fold change over the PBS/0 nM CGRP control group. Transwell migration towards CCL2 in the presence of CGRP (**e**) ( $n = 9$ ). Cell death in response to CGRP with or without TNF/IL-1 (**f**) ( $n = 7$ ). Macrophage efferocytosis of neutrophils after CGRP treatment (**g**) ( $n = 5$ ). Macrophage M2-like polarisation determined via CD206 expression in response to CGRP and IL-4/IL-13 (**h**) ( $n = 10$ ). **i**, Saline or TSP-1 (total 10  $\mu$ g) was injected in mouse skin wound borders at D1 and D3 post-injury or delivered in mouse quadriceps volumetric muscle loss defect via a fibrin hydrogel right after injury. Neutrophil and monocyte/macrophage (Mo/M $\Phi$ ) populations in injured tissues were analysed by flow cytometry at D3 post-delivery. CD206 level measurements were performed at D14 post-delivery ( $n = 6$ ). MFI is the geometric mean of fluorescence intensity. All data are plotted in box plots showing median (central line) and IQR (bounds). Whiskers show min. to max. range. Dots represent independent experiments. Two-tailed Student's *t*-test in **b, c, d, i**. One-way ANOVA with Tukey *post hoc* test for pair-wise comparisons in **e–h**. *P* values are indicated; n.s., non-significant.



**Extended Data Fig. 7 | Rescue of tissue healing in *Nav1.8<sup>Cre</sup>/Rosa26<sup>DTA</sup>* mice by local delivery of CGRP variants.** **a**, Design and amino acid sequences of wild-type CGRP and eCGRP. Disulfide bonds are indicated in yellow. Amid indicates amidation of the C-terminus phenylalanine. ECM-binding sequence from placenta growth factor (PIGF) is in red. Plasmin-sensitive site from vitronectin is in grey. **b**, CGRP and eCGRP were incubated with or without plasmin and analysed by SDS-PAGE. The gels show cleavage of the ECM-binding sequence in eCGRP by plasmin. Repeated independently 3 times. For gel source data, see Supplementary Figure 1. **c**, eCGRP activity was assessed using neutrophil and macrophage migration. The graphs show migration towards a chemoattractant (CXCL-1 or CCL2) in the presence of saline (PBS) or CGRP variants (20 nM). Results are expressed as fold change over saline control. Data are plotted in box plots showing median (central line) and IQR (bounds). Whiskers show min. to max. range. Dots represent individual experiments ( $n = 4$ ). **d**, Neutrophils and macrophages were isolated from *LysM<sup>Cre/+</sup>* and *LysM<sup>Cre/+</sup>/Ramp1<sup>fl/fl</sup>* mice. Cells were stimulated with CGRP or eCGRP (1 nM) for 30 min. cAMP concentration in cell lysates was measured by competitive ELISA ( $n = 4$ ). **e, f**, CGRP (1  $\mu$ g) or equimolar eCGRP was delivered intradermally or intramuscularly in *Nav1.8<sup>Cre</sup>/Rosa26<sup>DTA</sup>* mice. One day post-delivery, tissues were harvested and CGRP variants were detected by immunostaining. Representative skin and muscle tissue sections. CGRP signal coming from exogenous CGRP variants appears in green. Arrows indicate CGRP signal coming from  $\text{Na}_v1.8^+$  sensory neurons (in red). Nuclei are in blue. Scale bars = 50  $\mu$ m. Quantification of CGRP-positive area and signal intensity expressed as integrated density (**f**) ( $n = 5$  for skin,  $n = 4$  for


muscle). **g, h**, Saline, low dose of CGRP (250 ng), high dose of CGRP (500 ng), or equimolar eCGRP was delivered on *Nav1.8<sup>Cre</sup>/Rosa26<sup>DTA</sup>* mouse skin wounds (D1 post-injury for low dose and D1 and D3 post-injury for high dose). Skin wound closure D6 post-injury evaluated by histomorphometric analysis (**g**) ( $n = 16$  for saline;  $n = 8$  for low;  $n = 10$  for high). Representative skin histology (**h**). Black arrows indicate wound edges and red arrows indicate tips of epithelium tongue. Scale bar = 1 mm. **i, j**, Saline, low dose of CGRP (250 ng), high dose of CGRP (1  $\mu$ g), or equimolar eCGRP was delivered in *Nav1.8<sup>Cre</sup>/Rosa26<sup>DTA</sup>* mouse quadriceps volumetric muscle loss defect via a fibrin hydrogel. The extent of muscle regeneration (represented by the percentage of fibrotic tissue and muscle area) was evaluated by histomorphometric analysis of tissue sections at D8 (low dose) and D12 (high dose) post-injury (**i**) (D12:  $n = 6$ ; D8:  $n = 7$  for saline and high,  $n = 6$  for low). Representative histology (fibrotic tissue is stained dark blue; muscle tissue is stained red) (**j**). Scale bar = 1 mm. **k**, Mice received one injection of saline, CGRP (1  $\mu$ g), equimolar eCGRP, or capsaicin (positive control) in the right hind paw. Graphs show duration and frequency of nocifensive behaviours recorded for 5 min at various time points ( $n = 8$ ). **l**, Mice received one injection of saline, CGRP (1  $\mu$ g), or equimolar eCGRP in the right hind paw. Graph shows thermal withdrawal latency at various time points post-injection ( $n = 8$ ). All data are plotted in box plots showing median (central line) and IQR (bounds). Whiskers show min. to max. range. Dots represent independent experiments or injuries. One-way ANOVA with Tukey *post hoc* test for pair-wise comparisons in **c, d, g, i**. Two-tailed Student's *t*-test in **f**. Two-way ANOVA with Bonferroni *post hoc* test for pair-wise comparisons in **k, l**. *P* values are indicated; n.s., non-significant.



**Extended Data Fig. 8 | CGRP levels in *Lepr<sup>db/db</sup>* mice and TSP-1 deposition in response to eCGRP delivery.** **a**, CGRP expression in uninjured skin and muscle of wildtype (*Lepr<sup>+/+</sup>*) and diabetic (*Lepr<sup>db/db</sup>*) mice was detected by immunostaining of tissue sections. The graphs show quantification of CGRP-positive area ( $n = 6$ ). **b**, Skin wounds and muscle defects in *Lepr<sup>db/db</sup>* mice were treated with eCGRP. Expression of TSP-1 in granulation tissue was detected at D4 via immunostaining of tissue sections. TSP-1 in green, myeloid cells (CD11b)


in red, nuclei in blue. Scale bar = 200  $\mu\text{m}$ . Graphs show quantification of TSP-1-positive area, TSP-1 signal intensity expressed as integrated density and TSP-1-positive area in CD11b<sup>+</sup> cells ( $n = 6$ ). All data are plotted in box plots showing median (central line) and IQR (bounds). Whiskers show min. to max. range. Dots represent individual tissue sections. Two-tailed Student's *t*-test in **a,b**. *P* values are indicated.





**Extended Data Fig. 9 | Gating strategy to analyse wound immune cell dynamics in diabetic mice as well as cytokine and protease levels after eCGRP treatment. a.** Gating strategy to analyse myeloid cells skin and muscle post-injury. Flow cytometry dot plots representing the step by step (1–6) gating strategy to identify neutrophil (CD11b<sup>+</sup>, Ly6G<sup>+</sup>, F4/80<sup>-</sup>) and macrophage populations (CD11b<sup>+</sup>, F4/80<sup>+</sup>, Ly6G<sup>-</sup>). MFI is the geometric-mean of fluorescence intensity. **b.** Saline or eCGRP was delivered on *Lepr<sup>db/db</sup>* skin wounds or in

quadriceps volumetric muscle loss defect via a fibrin hydrogel. The levels of CCL2, IL-1 $\beta$ , CXCL2, MMP-2, and MMP-9 in injured tissues were quantified by ELISA ( $n = 8$  for skin,  $n = 4$  for muscle). Data are plotted in box plots showing median (central line) and IQR (bounds). Whiskers show min. to max. range. Dots represent individual injuries. Two-way ANOVA with Bonferroni *post hoc* test for pair-wise comparisons. *P* values are indicated.



**Extended Data Fig.10 | Summary of the neuro-immune-regenerative axis after acute injury in skin and muscle.** The schematic shows the proposed mechanisms by which nociceptors promote tissue healing via controlling neutrophils and monocytes/macrophages (Mo/MΦ) in injured tissues. Following tissue injury, CGRP-expressing nociceptor endings grow into the granulation tissue. CGRP signalling in neutrophils and macrophages induces the release of the ECM protein TSP-1. TSP-1 is deposited in the injured tissue milieu inhibiting neutrophil and monocytes/macrophage migration and

eventually accelerating the cell death response of neutrophils and macrophages to inflammatory cytokines. In addition, CGRP promotes efferocytosis and macrophage polarization into a M2-like phenotype via an autocrine or paracrine effect of TSP-1. Overall, nociceptors are critical for the transition of the injured tissue microenvironment towards a tissue healing phase. Blue line indicates inhibition, red line indicates induction. Dashed grey lines indicate that CGRP and TSP-1 may also promote tissue healing by acting on non-immune cells. Created with BioRender.com.

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

**Data collection** Leica AF6000LX and DMI8inverted Fluorescence microscope and Leica SP8 inverted confocal microscope for scanning immunostained slides. BD Fortessa for flow cytometry analysis. NextSeq2000 (Illumina) for RNA sequencing. PerkinElmer EnVision multi mode plate reader with EnSpire Manager software v2.00 for proliferation assay. LightCycle96 with software LightCycle96 SW 1.1 (Roche Diagnostics). C1000 Touch Thermal Cycler for complementary DNA (cDNA) preparation.

**Data analysis** Statistics: GraphPad Prism software (v9.3.1). Histology and immunofluorescence analysis: Fiji open source software (v2.14.0/1.54f) and Aperio ImageScope Viewer (v12.4.6.5003). Flow cytometry analysis: FlowJo v10. RNA sequencing analysis: STAR aligner (v2.7.0a), VolcaNoseR web tool (v1.0.3), Degust web tool (v41.1), and ShinyGO (v0.77) web tool.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

All data supporting the findings of this study are found within the manuscript and its Supplementary Information. Source data are provided with this paper. RNA sequencing data generated for this study are deposited in NCBI's Gene Expression Omnibus database (GSE255049). RNA-seq reads were mapped to the Mus musculus GRCm38.p6 genome.

## Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	N/A
Reporting on race, ethnicity, or other socially relevant groupings	N/A
Population characteristics	N/A
Recruitment	N/A
Ethics oversight	N/A

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	No statistical methods were used to predetermine sample size. Estimates were made based on our previous experience, availability and feasibility required to obtain statistically significant results: Martino, M. M. et al. Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing. <i>Science</i> 343, 885-888 (2014); Julier, Z. et al. Enhancing the regenerative effectiveness of growth factors by local inhibition of interleukin-1 receptor signaling. <i>Sci Adv</i> 6, eaba7602 (2020); Tan, J. L. et al. Restoration of the healing microenvironment in diabetic wounds with matrix-binding IL-1 receptor antagonist. <i>Commun Biol</i> 4, 422 (2021). This research comply with the 3Rs rule on reducing, replacing and refining the use of animals for scientific purpose. The simple size (n) for each experiment is provided in the figure legends.
Data exclusions	Data were not excluded from study reporting. Animals that showed signs of suffering were not included in study reporting.
Replication	Results shown are representative of at least 3 independently performed experiments. Each dot in the bar plots indicates a separate animal. All attempts at replication were successful.
Randomization	For all in vivo and in vitro experiments involving cells from animals, mice were preselected based on age and then randomly assigned to treatment groups.
Blinding	The experimenters were blinded to the mouse genotype or treatment conditions during surgical procedures. Histology and immunohistological analyses were blindly performed. Blinding was not performed for all other experiments due to availability of researchers.

## Reporting for specific materials, systems and methods

## Materials & experimental systems

## Methods

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern
<input checked="" type="checkbox"/>	<input type="checkbox"/> Plants

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Antibodies

### Antibodies used

Anti-mouse antibodies used in flow Cytometry in vivo:

1. FITC anti-CD11b (BioLegend, Clone M1/70, 6.6 µg/ml).
2. BV711 anti-CD11b (BioLegend, Clone M1/70, 2 µg/ml).
3. PE anti-F4/80 (BioLegend, Clone BM8, 4 µg/ml).
4. BV421 anti-Ly6G (BioLegend, Clone 1A8, 2 µg/ml).
5. BV711 anti-Ly6C (BioLegend, clone HK1.4, 1 µg/ml).
6. FITC anti-Ly6C (BioLegend, clone HK1.4, 5 µg/ml).
7. APC anti-CD206 (BioLegend, clone C068C2, 2 µg/ml).
8. PE-Cyanine7, anti-CD206 (BioLegend, clone C068C2, 2.6 µg/ml).
9. BV711 anti-CD3 (BioLegend, clone 17A2, 4 µg/ml).
10. PE-Cyanine7 anti-CD3 (BioLegend, clone 17A2, 4 µg/ml).
11. APC anti-CD4 (BioLegend, clone GK1.5, 2 µg/ml).
12. BV421 anti-CD8 (BioLegend, clone 53-6.7, 2 µg/ml).
13. PE anti-TCRβ (clone H57-597, 2 µg/ml).
14. APC/Fire 750 anti-TCR γ/δ (clone GL3, 2 µg/ml).
15. PE-Cyanine7 anti-CD11c (clone N418, 2 µg/ml).
16. APC/Fire 750 anti-MHC Class II (clone M5/114.15.2, 2 µg/ml).

Anti-mouse antibodies used in flow cytometry in vitro:

1. PE anti-CD11b (BioLegend, clone M1/70, 1 µg/ml).
2. BV711 anti-F4/80 (BioLegend, clone BM8, 2 µg/ml).
3. PE-Cyanine7 anti-CD206 (BioLegend, clone C068C2, 1 µg/ml).
4. APC anti-mouse arginase 1 (ThermoFisher, Clone AlexF5, 1 µg/ml).
5. APC anti-CD80 (BioLegend, clone 16-10A1, 0.5 µg/ml).

Immunostaining antibodies:

1. Rabbit anti-CGRP (66.7 µg/ml, Sigma, #C8198).
2. Rabbit anti-substance P (1:500, Immunostar, #20064).
3. Rabbit anti-vasoactive intestinal peptide (1:500, Immunostar, #20077).
4. Goat anti-galanin (1 µg/ml, Abcam, #99452).
5. Mouse anti-thrombospondin-1 (5 µg/ml, A6.1, Thermo Fisher Scientific, #14-9756-82).
6. Rat anti-CD11b (5 µg/ml, M1/70, Thermo Fisher Scientific, #14-0112-82).
7. Unconjugated AffiniPure Fab Fragment Goat Anti-Mouse IgG (H+L) (Jackson ImmunoResearch Labs, #115-007-003, 100 µg/ml).
8. F(ab')<sub>2</sub>-Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 (2.6 µg/ml, Thermo Fisher Scientific, #A-11070).
9. Donkey anti-goat IgG H&L conjugated with Alexa Fluor 488 (2.6 µg/ml, Thermo Fisher Scientific, #A-11055).
10. Goat anti-mouse (IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 488, 2.6 µg/ml, Thermo Fisher Scientific, #A48286TR).
11. Goat anti-Rat (IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 594, 2.6 µg/ml, Thermo Fisher Scientific, #A48264).
12. Rabbit anti-Ramp-1 (8.5 µg/ml, Alomone Lab, #ARR-021).
13. Rabbit anti-calcitonin receptor like receptor (5 µg/ml, Biorbyt, #orb526584).
14. Rat anti-mouse Ki-67 (5 µg/ml, Thermo Fisher Scientific, #14-5698-82).
15. Mouse anti-mouse cytokeratin 14 (4 µg/ml, Thermo Fisher Scientific, #MAS-11599).
16. Goat anti-mouse Alexa Fluor-647 (2 µg/ml, Thermo Fisher Scientific, #A-21235).
17. Goat anti-rat Alexa Fluor-488 (2.67 µg/ml, Thermo Fisher Scientific, #A48262TR).
18. Unconjugated affinity-purified F(ab) fragment anti-mouse IgG (H+L) (10 µg/ml, Jackson ImmunoResearch, #AB\_2338476).

### Validation

All BioLegend primary antibodies for flow cytometry were validated by the manufacturer on C57BL/6 mouse bone marrow cells, C57BL/6 mouse splenocytes or BALB/c mouse peritoneal macrophages.  
 APC anti-mouse arginase 1 was validated on normal human lysed whole blood cells by the manufacturer.  
 Rabbit anti-CGRP was validated by the manufacturer with immunohistochemistry of trigeminal ganglia cell cultures at a dilution of 1:200 and with immunocytochemistry of mouse lung slices at a dilution of 1:500.  
 Rabbit anti-substance P was validated by the manufacturer using soluble pre-adsorption with substance P at a final concentration of 10 µg of peptide per ml of diluted anti-substance P.

Rabbit anti-vasoactive intestinal peptide was validated by the manufacturer using soluble pre-adsorption with vasoactive intestinal peptide at a final concentration of 10-5 M.  
 Goat anti-galanin was validated on mouse samples by Labome (ab99452).  
 Mouse anti-thrombospondin-1 was validated on mouse brain tissue sections by the manufacturer.  
 Rat anti-CD11b (M1/70, same clone as the anti-CD11b from Biolegend) was validated by the manufacturer using immunostaining of formalin-fixed paraffin-embedded human colon adenocarcinoma tissue sections.  
 Rabbit anti-Ramp-1 was validated by the manufacturer using immunostaining of living rat pheochromocytoma (PC12) cells.  
 Rabbit anti-calcitonin receptor like receptor was validated by our lab on mouse neutrophils and macrophages.  
 Rat anti-mouse Ki-67 was validated by the manufacturer using immunostaining of formalin-fixed paraffin-embedded mouse thymus tissue sections.  
 Mouse anti-mouse cytokeratin 14 was validated by the manufacturer using immunostaining of 70% confluent log phase A-431 cells.

## Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)	Human umbilical vein endothelial cells were purchased from Sigma-Aldrich (Catalog #200P-05N). C2C12 mouse myoblast cell line were purchased from Cell Bank (Australia, Code 91031101). HaCaT keratinocyte cell line was gifted by Professor Richard Boyd (Monash University, Australia).
Authentication	HUVEC: cells were authenticated by the supplier using morphology and staining for VEGFR2 and CD31. C2C12: cells were originally obtained from ATCC and authenticated by ATCC and our lab using morphology. HaCat: cells were authenticated by Professor Ricard Boyd's lab and our lab using morphology.
Mycoplasma contamination	Cells obtained from vendors were certified negative for mycoplasma contamination.
Commonly misidentified lines (See <a href="#">ICLAC</a> register)	No commonly misidentified cell lines were used in the study.

## Animals and other research organisms

Policy information about [studies involving animals; ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals	<p>C57BL6/J were from from the Monash Animal Research Platform. 10-12-week-old mice were used.</p> <p>Nav1.8Cre<sup>+/+</sup> mice (B6.129-Scn10a<sup>tm2</sup>(cre)Jnw/H B6, stock ID EM:04582, European Mouse Mutant Archive) were used for in vitro fertilisation to generate Nav1.8Cre<sup>+/-</sup> mice on a C57BL/6J background in house.</p> <p>Rosa26DTA<sup>+/+</sup> (B6.129-Gt(ROSA)26Sortm1(DTA)Mrc/J, strain 010527, Jackson Laboratory) were maintained on a C57BL/6J background in house.</p> <p>Nav1.8Cre<sup>+/-</sup> mice were bred with Rosa26DTA<sup>+/+</sup> to generate Nav1.8Cre<sup>+/-</sup>/Rosa26DTA<sup>+/-</sup> mice and Nav1.8Cre<sup>-/-</sup>/Rosa26DTA<sup>+/-</sup>. 10-12-week-old mice were used.</p> <p>Rosa26tdT reporter mice (B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J, strain 007914, Jackson Laboratory).</p> <p>Rosa26tdT mice were bred with Nav1.8Cre<sup>+/+</sup> mice to generate Nav1.8Cre<sup>+/-</sup>/Rosa26Tdt<sup>+/-</sup>. 10-12-week-old mice were used.</p> <p>BKS.Cg-Dock7 m <sup>+/+</sup> Lepr db /J (Lepr db/db) mice were obtained from the Jackson Laboratory and bred in house. 12-14-week-old mice were used.</p> <p>B6.129S2-Ramp1<sup>&lt;tm1.2Tsu&gt;</sup> sperm was kindly provided by Prof. Kazutake Tsujikawa (Graduate School and School of Pharmaceutical Sciences, Osaka University). B6.129S2-Ramp1<sup>&lt;tm1.2Tsu&gt;</sup> sperms were used for in vitro fertilisation to generate Ramp1<sup>fl/+</sup> mice. Ramp1<sup>-/-</sup> mice were generated by crossing Ramp1<sup>fl/fl</sup> mice with CAGcre mice (C57BL/6-Tg(CAG-cre)13Miya, RIKEN BioResource Research Center, strain 09807). 10-12-week-old mice were used.</p> <p>Ramp1<sup>fl/fl</sup>/LysMCre<sup>+/-</sup> mice were bred in house by crossing Ramp1<sup>fl/fl</sup> with LysMCre<sup>+/+</sup> mice (B6.129P2-Lyzs<sup>&lt;tm1</sup>(cre)lfo&gt;, RIKEN BioResource Research Center, strain 02302). LysMCre<sup>+/-</sup> littermates were used as controls. 10-12-week-old mice were used.</p> <p>Mice constitutively expressing tdTomato were obtained by crossing with B6.C-Tg(CMV-cre)1Cgn/J (8-10-week-old, Jackson Laboratory, strain 006054) with Rosa26DTA<sup>+/+</sup> mice.</p>
Wild animals	No wild animals were used.
Reporting on sex	<p>All in vitro experiments were performed by using male mouse bone marrow cells.</p> <p>C57BL6/J mice: male and female.</p> <p>Nav1.8Cre<sup>+/-</sup>/Rosa26DTA<sup>+/-</sup> and Nav1.8Cre<sup>-/-</sup>/Rosa26DTA<sup>+/-</sup> mice: male.</p> <p>Nav1.8Cre<sup>+/-</sup>/Rosa26DTA<sup>+/-</sup> mice when treated with CGRP variants or saline: male (muscle experiments) and female (skin experiments).</p> <p>Nav1.8Cre<sup>+/-</sup>/Rosa26Tdt<sup>+/-</sup> mice: male.</p> <p>BKS.Cg-Dock7 m <sup>+/+</sup> Lepr db /J (Lepr db/db) mice: male (muscle experiments) and female (skin experiments).</p> <p>Ramp1<sup>-/-</sup> mice: male.</p> <p>Ramp1<sup>fl/fl</sup> with LysMCre<sup>+/-</sup> mice: male.</p> <p>LysMCre<sup>+/-</sup> mice: male.</p>

Field-collected samples

Ethics oversight

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Flow Cytometry

### Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

### Methodology

Sample preparation

In vivo immune cell profiling:

Skin wounds were harvested using an 8 mm biopsy punch, and muscle defects were dissected to isolate the quadriceps. Tissue samples were minced with scissors and subjected to two serial digestions with collagenase XI (1 mg/ml) at 37°C (30 minutes for skin, 20 minutes for muscle). After the first digestion, the supernatant was collected and mixed with neutralization buffer (DMEM/F12 with 5 mM EDTA). The first collection was kept on ice, and fresh collagenase XI was added to the undigested tissue for the second digestion. Digestion mixtures were passed through a 70 µm cell strainer.

In vitro macrophages:

Mouse bone marrow cells derived-macrophages were treated with different cytokines with or without CGRP (1 or 20 nM) for 24-72 hours. Cells were then detached with TrypLE (Gibco) containing 3 mM EDTA and harvested in culture medium containing 10% FBS for further analysis.

In vitro neutrophils:

Mouse neutrophils were isolated from mouse bone marrow by using EasySep Mouse Neutrophil Enrichment Kit (STEMCELL Technologies). Isolated cells were treated with different cytokines with or without CGRP (1 or 20 nM) for further analysis.

Instrument

BD Fortessa X20.

Software

FlowJo Software v10 for analysis.

Cell population abundance

There was no cell sorting experiments.

Gating strategy

All the gating strategies are based on FMOs (Fluorescence Minus One).

Skin or muscle neutrophils (CD11b+ Ly6G+) were gated from live cells.

Skin or muscle monocytes/macrophages (CD11b+F4/80+ ) were gated by excluding Ly6G from the live cells.

Skin or muscle Ly6Chigh cells: Ly6Chigh population was gated from CD11b+ F4/80+ cells.

CD206 expression in skin or muscle macrophages: CD206 expression was determined in the macrophage population (F4/80+ CD11b+, Ly6G-).

Skin or muscle dendritic cells ( CD11c+ MHC-II+) were gated by excluding neutrophils and macrophages from the live cells.

Skin or muscle CD4 T cells (CD3+ CD4+) were gated by excluding CD11b+ from the live cells.

Skin or muscle CD8 T cells: (CD3+ CD8+) were gated by excluding CD11b+ from the live cells.

Skin or muscle γδ T cells (CD3+ TCRCγ+ TCRβ-) were gated by excluding CD11b+ from the live cells.

Skin or muscle tdTomato cells were gated using the strategy above and using FMO for tdTomato.

- Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.